世界防疫专利信息表

时间区间

按申请日

  • 世界防疫专利信息表:1912.04-2019.08

按公告日

  • 世界防疫专利信息表:1913.06-2019.10

字段展示

世界防疫专利信息表
分类
分类号
代理人
PDF下载地址
摘要
申请日
国家/组织
公开/公告日
引用专利
主分类号
申请号
发明人
主权利要求
公开/公告号
申请人

样本数据

分类分类号代理人摘要申请日国家/组织公开/公告日引用专利主分类号申请号发明人主权利要求公开/公告号申请人
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/53;A61K31/664;A61K31/675;A61K31/683;A61K31/685;A61P31/12Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula (I): wherein the 1' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.20160916WO(世界知识产权局)20170323WO2010002877A2;WO2014078778A2;WO2014116755A1;US2012071434A1;US8008264B2;US2012027752A1;WO2009132135A1;US2012009147A1;WO2012142085A1;WO2012075140A1;US2013143835A1A61K31/53WO2016US52092CLARKE MICHAEL O' NEIL HANRAHAN;FENG JOY YANG;JORDAN ROBERT;MACKMAN RICHARD L;RAY ADRIAN S;SIEGEL DUSTINWO2017049060A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/706;A61K45/06wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.20160916US(美国)20170316A61K31/706US201615267433CLARKE MICHAEL O' NEIL HANRAHAN;FENG JOY YANG;JORDAN ROBERT;MACKMAN RICHARD L;RAY ADRIAN S;SIEGEL DUSTINUS2017071964A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/706;A61K31/7056wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.20190201US(美国)20190822A61K31/706US201916265016CLARKE MICHAEL O' NEIL HANRAHAN;FENG JOY YANG;JORDAN ROBERT;MACKMAN RICHARD L;RAY ADRIAN S;SIEGEL DUSTINUS2019255085A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/706;A61P31/12Provided are methods of treating feline Coronavirus infections comprising administering a therapeutically effective amount of aza-sugar containing nucleoside analogs or pharmaceutically acceptable salts thereof.20180313WO(世界知识产权局)20180920A61K31/706WO2018US22166PERRON MICHEL JOSEPHWO2018169946A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/724;A61K9/19;A61K47/40;A61K47/69;A61P31/12The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.20180710US(美国)20190321A61K31/724US201816031620LARSON NATEUS2019083525A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07D487/04;C07D519/00;C07F9/24;C07F9/6561Provided are methods of preparing compounds and pharmaceutical compositions for treating Filoviridae virus infections The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.20151029US(美国)20160505US8980865B2;US9243022B2;US9249174B2;US9605018B2;US9724360B2;US9388208B2;US9481703B2;US9487544B2;US9540411B2;US9701682B2;US2015133395A1C07D487/04US201514926063AXT STEVEN DONALD;BADALOV PAVEL ROBERTOVICH;BRAK KATRIEN;CAMPAGNA SILVIO;CHTCHEMELININE ANDREI;DOERFFLER EDWARD;FRICK MORIN MAE;GAO DETIAN;HEUMANN LARS V;HOANG BRITTANIE;LEW WILLARD;MILBURN ROBERT RONALD;NEVILLE SEAN TIMOTHY;ROSS BRUCE;RUEDEN ERIK;SCOTT ROBERT WILLIAM;SIEGEL DUSTIN;STEVENS ANDREW C;TADEUS CLARISSA;VIEIRA TIAGO;WALTMAN ANDREW W;WANG XIANGHONG;WHITCOMB MARK CHARLES;WOLFE LYDIA;YU CHIA-YUNUS2016122356A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/706;A61K31/00;A61K31/53;A61K31/6615;A61K31/665;A61K31/675;A61K31/683;A61K31/685;A61K31/7056;A61K45/06;C07D487/04;C07D519/00;C07F9/24;C07F9/6561;C07H1/00;C07H1/02;C07H11/00;C07H15/18Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.20180222US(美国)20190409US8008264B2;US8318682B2;US8853171B2;US9724360B2;US9949994B2;US4816570A;US4968788A;US5663159A;US5792756A;US6312662B1;US6476030B1;US6656915B1;US6909011B2;US7105493B2;US7125855B2;US7176203B2;US7268119B2;US7285658B2;US7368437B1;US7429571B2;US7514410B2;US7560434B2;US7598230B2;US7608597B2;US7713941B2;US7807653B2;US7842672B2;US7973013B2;US7994139B2;US8012941B2;US8012942B2;US8071568B2;US8119607B2;US8242085B2;US8415308B2;US8455451B2;US8871737B2;US8980865B2;US9090642B2;US9243022B2;US9249174B2;US9278990B2;US9388208B2;US9481703B2;US9487544B2;US9540411B2;US9605018B2;US9701682B2;US2003050229A1;US2004006002A1;US2004023901A1;US2004063658A1;US2004067901A1;US2004138170A1;US2005187180A1;US2005215513A1;US2005250728A1;US2006058303A1;US2006241064A1;US2008107628A1;US2008161324A1;US2008280842A1;US2009004138A1;US2009221524A1;US2009233879A1;US2009317361A1;US2010015094A1;US2010016251A1;US2010021425A1;US2010035835A1;US2010035836A1;US2010203015A1;US2010234584A1;US2010291031A2;US2010298257A1;US2011070194A1;US2011230654A1;US2011257122A1;US2011293563A1;US2012009147A1;US2012020921A1;US2012027752A1;US2012071434A1;US2012107274A1;US2013034521A1;US2013143835A1;US2013281686A1;US2013315868A1;US2013344028A2;US2015111839A1;US2015133395A1;US2015152116A1;AU2010295392B2;CA2367921C;CN1291994A;CN1443189A;CN1498221A;CN1852915A;CN101043893A;CN101611046A;CN102906102A;EA201071170A1;EA201171417A1;EA201200525A1;EP2480559A1;EP2396340B1;JPH1017629A;JP2004520367A;JP2008502685A;JP2008518934A;TWI401084B;WO9119721A1;WO0056734A1;WO0132153A2;WO0160315A2;WO0190121A2;WO0208241A2;WO0218404A2;WO0232920A2;WO02057287A2;WO02057425A2;WO03093272A1;WO03093273A1;WO03100009A2;WO2004046331A2;WO2005009418A2;WO2005123087A2;WO2006031725A2;WO2006050161A2;WO2006065335A2;WO2006121820A1;WO2007027248A2;WO2007056170A2;WO2007064883A2;WO2007064931A2;WO2007065289A2;WO2007097991A2;WO2007135134A1;WO2008005542A2;WO2008055870A1;WO2008079206A1;WO2008082601A2;WO2008085508A2;WO2008089105A2;WO2008116064A2;WO2008121634A2;WO2008141079A1;WO2009009951A1;WO2009131926A1;WO2009132123A1;WO2009132135A1;WO2010002877A2;WO2010036407A2;WO2010093608A1;WO2010099458A1;WO2010135569A1;WO2011011303A1;WO2010111381A2;WO2011035231A1;WO2011035250A1;WO2011123645A2;WO2011123672A1;WO2011150288A1;WO2012012465A1;WO2012012776A1;WO2012039787A1;WO2012039791A1;WO2012051570A1;WO2013084165A1;WO2014042433A2;WO2014078778A2;WO2014116755A1;WO2015069939A1;WO2016069825A1;WO2016069826A1;WO2016069827A1;WO2017049060A1A61K31/706US201815902690CHUN BYOUNG KWON;CLARKE MICHAEL O'NEIL HANRAHAN;DOERFFLER EDWARD;HUI HON CHUNG;JORDAN ROBERT;MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;SIEGEL DUSTINUS10251898B2GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H15/18;A61K31/00;A61K31/53;A61K31/675;A61K31/685;A61K45/06;C07D487/04;C07D519/00;C07F9/24;C07F9/6561;C07H1/00;C07H1/02;C07H7/06;C07H11/00Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.20160824US(美国)20180424US4816570A;US4968788A;US5663159A;US5792756A;US6312662B1;US6476030B1;US6656915B1;US6909011B2;US7105493B2;US7125855B2;US7176203B2;US7268119B2;US7285658B2;US7368437B1;US7429571B2;US7514410B2;US7560434B2;US7598230B2;US7608597B2;US7713941B2;US7807653B2;US7842672B2;US7973013B2;US7994139B2;US8008264B2;US8012941B2;US8012942B2;US8071568B2;US8119607B2;US8242085B2;US8318682B2;US8415308B2;US8455451B2;US9090642B2;US9724360B2;US2003050229A1;US2004006002A1;US2004023901A1;US2004063658A1;US2004067901A1;US2004138170A1;US2005187180A1;US2005215513A1;US2005250728A1;US2006058303A1;US2006241064A1;US2008107628A1;US2008161324A1;US2008280842A1;US2009004138A1;US2009221524A1;US2009233879A1;US2009317361A1;US2010015094A1;US2010016251A1;US2010021425A1;US2010035835A1;US2010035836A1;US2010203015A1;US2010234584A1;US2010291031A2;US2010298257A1;US2011070194A1;US2011230654A1;US2011257122A1;US2011293563A1;US2012009147A1;US2012020921A1;US2012027752A1;US2012107274A1;US2013034521A1;US2013143835A1;US2013281686A1;US2013344028A2;US2015111839A1;US2015152116A1;CA2367921C;CN1291994A;CN1443189A;CN1498221A;CN1852915A;CN101043893A;CN101611046A;CN102906102A;EA201071170A1;EA201171417A1;EA201200525A1;EP2396340B1;JPH1017629A;JP2004520367A;JP2008502685A;JP2008518934A;TWI401084B;WO9119721A1;WO0056734A1;WO0132153A2;WO0160315A2;WO0190121A2;WO0208241A2;WO0218404A2;WO0232920A2;WO02057287A2;WO02057425A2;WO03093272A1;WO03093273A1;WO03100009A2;WO2004046331A2;WO2005009418A2;WO2005123087A2;WO2006031725A2;WO2006050161A2;WO2006065335A2;WO2006121820A1;WO2007027248A2;WO2007056170A2;WO2007064883A2;WO2007064931A2;WO2007065289A2;WO2007097991A2;WO2007135134A1;WO2008005542A2;WO2008079206A1;WO2008082601A2;WO2008085508A2;WO2008089105A2;WO2008116064A2;WO2008121634A2;WO2008141079A1;WO2009009951A1;WO2009131926A1;WO2009132123A1;WO2009132135A1;WO2010002877A2;WO2010036407A2;WO2010093608A1;WO2010099458A1;WO2010135569A1;WO2010111381A2;WO2011035231A1;WO2011035250A1;WO2011123645A2;WO2011123672A1;WO2011150288A1;WO2012012465A1;WO2012012776A1;WO2012039787A1;WO2012039791A1;WO2012051570A1;WO2013084165A1;WO2014042433A2;WO2015069939A1C07H15/18US201615246240CHUN BYOUNG KWON;CLARKE MICHAEL O'NEIL HANRAHAN;DOERFFLER EDWARD;HUI HON CHUNG;JORDAN ROBERT;MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;SIEGEL DUSTINUS9949994B2GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07D487/04;A61K9/00;A61K31/706;A61K45/06;C07F9/6561;C07H7/06;C07H19/04Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.20150204US(美国)20180904US9090642B2;US4816570A;US4968788A;US5663159A;US5792756A;US6312662B1;US6476030B1;US6656915B1;US6909011B2;US7105493B2;US7125855B2;US7176203B2;US7268119B2;US7285658B2;US7368437B1;US7429571B2;US7514410B2;US7560434B2;US7598230B2;US7608597B2;US7713941B2;US7807653B2;US7842672B2;US7973013B2;US7994139B2;US8008264B2;US8012941B2;US8012942B2;US8071568B2;US8119607B2;US8242085B2;US8318682B2;US8415308B2;US8455451B2;US2003050229A1;US2004006002A1;US2004023901A1;US2004063658A1;US2004067901A1;US2004138170A1;US2005187180A1;US2005215513A1;US2005250728A1;US2006058303A1;US2006241064A1;US2008107628A1;US2008161324A1;US2008280842A1;US2009004138A1;US2009221524A1;US2009233879A1;US2009317361A1;US2010015094A1;US2010016251A1;US2010021425A1;US2010035835A1;US2010035836A1;US2010203015A1;US2010234584A1;US2010291031A2;US2010298257A1;US2011070194A1;US2011230654A1;US2011257122A1;US2011293563A1;US2012009147A1;US2012020921A1;US2012027752A1;US2012107274A1;US2013034521A1;US2013281686A1;US2013344028A2;CA2367921C;CN1443189A;CN1498221A;CN1852915A;CN1291994C;CN101043893A;CN101611046A;CN102906102A;EA201071170A1;EA201171417A1;EA201200525A1;EP2396340B1;JPS4117629B1;JP2004520367A;JP2008502685A;JP2008518934A;TWI401084B;WO9119721A1;WO0056734A1;WO0132153A2;WO0160315A2;WO0190121A2;WO0208241A2;WO0218404A2;WO0232920A2;WO02057287A2;WO02057425A2;WO03093272A1;WO03093273A1;WO03100009A2;WO2004046331A2;WO2005009418A2;WO2005123087A2;WO2006031725A2;WO2006050161A2;WO2006065335A2;WO2006121820A1;WO2007027248A2;WO2007056170A2;WO2007064883A2;WO2007064931A2;WO2007065289A2;WO2007097991A2;WO2007135134A1;WO2008005542A2;WO2008079206A1;WO2008082601A2;WO2008085508A2;WO2008089105A2;WO2008116064A2;WO2008121634A2;WO2008141079A1;WO2009009951A1;WO2009131926A1;WO2009132123A1;WO2009132135A1;WO2010002877A2;WO2010036407A2;WO2010093608A1;WO2010099458A1;WO2010111381A2;WO2010135569A1;WO2011035231A1;WO2011035250A1;WO2011123672A1;WO2011123645A2;WO2011150288A1;WO2012012465A1;WO2012012776A1;WO2012039787A1;WO2012039791A1;WO2012051570A1C07D487/04US201514613719MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNESUS10065958B2GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/23;A61K31/706;A61P31/16Provided are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.20130311WO(世界知识产权局)20130919WO0232920A2;WO2009132123A1;WO2009132135A1;WO2012037038A1C07H19/23WO2013US30196CLARKE MICHAEL O' NEIL HANRAHANWO2013138236A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/23as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.20160930US(美国)20170427C07H19/23US201615282492CLARKE MICHAEL O' NEIL HANRAHANUS2017114086A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/23;A61K31/706;A61K45/06;C07H19/12as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.20180622US(美国)20190117C07H19/23US201816016369CLARKE MICHAEL O' NEIL HANRAHANUS2019016749A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/706;A61P31/16;C07H7/06;C07H21/04Provided are methods for treating Orthomyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I wherein R2 is halogen. The compounds, compositions, and methods provided particularly useful for the treatment of Human Influenza virus infections.20110912WO(世界知识产权局)20120322WO2010002877A2;WO03062257A1;WO0232920A2;WO0056734A1;WO2008089105A2;WO2008141079A1;WO2009132123A1;WO2009132135A1;US4816570A;US4968788A;US5663159A;US5792756A;WO9119721A1;US6312662B1;US5458135A;US5740794A;US5775320A;US5785049A;US3906950A;US4013075A;US4069819A;US4995385A;US5522385A;US4668218A;US4667668A;US4805811A;US5388572A;US5261538A;US5544647A;US5622163A;US4955371A;US3565070A;US3361306A;US6116234AA61K31/706WO2011US51249CLARKE MICHAEL O' NEIL HANRAHAN;KIM CHOUNG U;LEW WILLARDWO2012037038A1GILEAD SCIENCES INC;CLARKE MICHAEL O' NEIL HANRAHAN;KIM CHOUNG U;LEW WILLARD
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07F9/6558;C07D487/04wherein R2 is halogen. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.20170124US(美国)20170810C07F9/6558US201715414351CLARKE MICHAEL O' NEIL HANRAHAN;KIM CHOUNG U;LEW WILLARDUS2017226140A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/23;A61K31/706;A61P31/16Disclosed herein are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds, wherein the variables are as defined in the specification. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.20130311NZ(新西兰)20161028C07H19/23NZ20130629996CLARKE MICHAEL O’ NEIL HANRAHANNZ629996AGILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/23;A61K31/706;A61P31/16Provided are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.20171219AU(澳大利亚)20180118C07H19/23AU20170279590CLARKE MICHAEL O'NEIL HANRAHANAU2017279590A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/12;A61K31/706;A61K45/06Provided are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.20130311US(美国)20130919US2011230654A1;US8008264B2;US8318682B2;US8012941B2C07H19/12US201313793557CLARKE MICHAEL O'NEIL HANRAHANUS2013243725A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H17/02;A61K31/706;A61K45/06Provided are methods for treating Orthomyxoviridue virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein R2 is halogen. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.20140124US(美国)20140717C07H17/02US201414163251CLARKE MICHAEL O'NEIL HANRAHAN;KIM CHOUNG U;LEW WILLARDUS2014200188A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H7/06;A61K9/00;A61K31/706;A61K45/06Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.20141222US(美国)20150423US2008161324A1;US2010249068A1;US8853171B2;US8012941B2;US8318682B2;US8008264B2;WO2009132135A1C07H7/06US201414579348MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AUS2015111839A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07D309/10;C07H19/00Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (I): wherein the 1 ' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.20170223AU(澳大利亚)20190502WO2009132135A1C07D309/10AU20170201230MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNESAU2017201230B2GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07D309/10;C07H19/00Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (I): wherein the I 'position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.20190723AU(澳大利亚)20190808C07D309/10AU20190208167MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNESAU2019208167A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07D309/10;C07H19/00Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (I): wherein the 1 ' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.20110722WO(世界知识产权局)20120126WO2009132135A1;WO2010002877A2;WO2008141079A1;WO2008089105A2;WO0056734A1;US4816570A;US4968788A;US5663159A;US5792756A;WO9119721A1;US6312662B1;US5458135A;US5740794A;US5775320A;US5785049A;US3906950A;US4013075A;US4069819A;US4995385A;US5522385A;US4668218A;US4667668A;US4805811A;US5388572A;US5261538A;US5544647A;US5622163A;US4955371A;US3565070A;US3361306A;US6116234AC07D309/10WO2011US45102MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNESWO2012012776A1GILEAD SCIENCES INC;MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/706;A61K39/395;A61P31/12;C07H19/04Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.20110722US(美国)20120202US2008161324A1;WO2009132135A1A61K31/706US201113189373MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNESUS2012027752A1MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES;GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07D487/04;C07F9/6561Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.20150204US(美国)20150604C07D487/04US201514613719MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNESUS2015152116A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07D487/04;A61K9/00;A61K31/706;A61K45/06;C07F9/6561;C07H7/06;C07H19/04wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.20180723US(美国)20190221C07D487/04US201816042085MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNESUS2019055251A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07D473/18;C07H19/16;A61K31/513;A61K31/52;A61K31/522;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61P3/12;A61P31/12;A61P35/00;A61P35/02;C07D405/04;C07D473/30;C07D473/34;C07H19/048;C07H19/06;C07H19/067;C07H19/10;C07H19/167;C07H19/20;C07H21/04;C12Q1/68The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction ("RT-PCR"). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.20130603US(美国)20140227US6080791A;US6348587B1;WO0191737A2C07D473/18US201313908098STUYVER LIEVEN;WATANABE KYOICHIUS2014057863A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/00;A61P31/14The present invention relates to novel salts and crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo2,1-ftriazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate for use in treating viral infections. In some embodiments, the viral infection is caused by a virus selected from the group consisting of Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, and Paramyxoviridae.20180427US(美国)20181206C07H19/00US201815964597BRAK KATRIEN;CARRA ERNEST A;HEUMANN LARS V;LARSON NATEUS2018346504A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61P31/14;A61K31/53;C07F9/6561The present invention relates to novel salts and crystalline forms of (S)-2-ethylbutyl2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo2,1- ftriazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl) methoxy)(phenoxy)phosphoryl)amino)propanoate (Formula I) for use in treating viral infections. In some embodiments, the viral infection is caused by a virus selected from the group consisting of Arenaviridae, Coronaviridae, Fil oviridae, Fiaviviridae,and Paramyxoviridae.20180427WO(世界知识产权局)20181108US201662325419P;US201514926062A;US2015057933WA61P31/14WO2018US29974BRAK KATRIEN;CARRA ERNEST A;HEUMANN LARS V;LARSON NATEWO2018204198A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/08;A61K31/4178;A61K31/506;A61K45/06;C07D403/04The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses.20160128US(美国)20180118A61K31/08US201615546818RADTKE KATHERINE L;PETERS HANNAH L;NEYTS JOHAN;JOCHMANS DIRK;SNIJDER ERIC JUS2018015052A1UNIV MARYLAND;UNIV LEUVEN KATH;LEIDEN UNIV MEDICAL CENTER
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/08;A61K31/4178;A61K31/506;A61K45/06;C07D403/04The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses.20180702US(美国)20181025A61K31/08US201816025284RADTKE KATHERINE L;PETERS HANNAH;NEYTS JOHAN;JOCHMANS DIRK;SNIJDER ERIC JUS2018303768A1UNIV MARYLAND
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/08;A61K31/4178;A61K31/506;A61K45/06;C07D403/04The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses.20190312US(美国)20190704A61K31/08US201916299379RADTKE KATHERINE L;PETERS HANNAH;NEYTS JOHAN;JOCHMANS DIRK;SNIJDER ERIC JUS2019201352A1UNIV MARYLAND;UNIV LEUVEN KATH;LEIDEN UNIV MEDICAL CENTER
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/706;A61P31/12Provided are methods of treating feline Coronavirus infections comprising administering a therapeutically effective amount of aza-sugar containing nucleoside analogs or pharmaceutically acceptable salts thereof.20180313WO(世界知识产权局)20180920A61K31/706WO2018US22166PERRON MICHEL JOSEPHWO2018169946A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07D307/12;A61K31/505;C07D239/10;C07D405/04Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.20190307WO(世界知识产权局)20190912C07D307/12WO2019US21168PAINTER GEORGE R;PERRYMAN DAVID;BLUEMLING GREGORY RWO2019173602A1UNIV EMORY
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/365;A61K31/381Infection by a Coronaviridae virus (e.g., a coronavirus) and/or illness due to a Coronaviridae virus are treated or protected against by administration of a therapeutically or prophylactically effective amount of certain nucleoside compounds and derivatives thereof, either alone or in a composition comprising the nucleoside compound or its derivative and a pharmaceutically acceptable carrier. In addition, replication of a Coronaviridae virus is inhibited by administration of the nucleoside compounds and derivatives thereof, either alone or in pharmaceutical compositions. The nucleosides are particularly suitable for use in treating or prophylaxis of an infection by the SARS virus and/or in treating or prophylaxis of SARS, and for use in inhibiting replication of the SARS virus. The nucleoside compounds and derivatives can optionally be administered in combination with other agents active against the Coronaviridae virus and/or an illness due to the virus. The nucleoside compounds are also for use in the manufacture of medicaments for the inhibition of Coronaviridae virus replication, for the treatment or prophylaxis of Coronaviridae virus infection, and/or for the treatment or prophylaxis of an illness due to a Coronaviridae virus (e.g., the SARS virus). In addition, the compounds are for use as medicaments for the inhibition of Coronaviridae virus replication, for the treatment or prophylaxis of Coronaviridae virus infection, and/or for the treatment or prophylaxis of an illness due to a Coronaviridae virus.20040427US(美国)20041223US2003050229A1;US2003060400A1;US6777395B2;US2002147160A1;US6812219B2A61K31/365US20040832945OLSEN DAVID B;TOMASSINI JOANNE E;MAO SHI-SHAN;CARROLL STEVEN SUS2004259934A1
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/04;A61K31/7052;A61P31/12;C07H19/056;C07H19/06Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection.20110919WO(世界知识产权局)20120329WO2008086042A2;EP0457326A1;WO2009067409A1;WO2007020193A2C07H19/04WO2011US52217BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMARWO2012040124A1ALIOS BIOPHARMA INC;BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMAR
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708Disclosed herein are nucleosides, nucleotides and analogs thereof of formula I, II and III, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. In particular, viral infections caused by a virus selected from henipavirus, a morbillivirus, a respirovirus, a rubulavirus and a metapneumovirus.20130319NZ(新西兰)20161028A61K31/7068NZ20130629428SMITH DAVID BERNARD;DEVAL JEROME;BEIGELMAN LEONID;PRHAVC MARIJA;WANG GUANGYINZ629428AALIOS BIOPHARMA INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/70;A01N43/04;A61K31/7056;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61K31/7105;A61K45/06;C07H19/00;C07H19/04;C07H19/048;C07H19/056;C07H19/067;C07H19/073;C07H19/09;C07H19/10;C07H19/11;C07H19/167;C07H19/173;C07H19/19;C07H19/20Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection.20110919US(美国)20141104US7094768B2;US7151089B2;US7629328B2;US5449664A;US5681940A;US5712378A;US6787525B1;US7915232B2;US2003064945A1;US2003124513A1;US2004259934A1;US2006040890A1;US2007042988A1;US2007066815A1;US2008008682A1;US2008039428A1;US2008107628A1;US2008161254A1;US2008188458A1;US2009176732A1;US2009318380A1;US2010151001A1;US2010234584A1;US2010240604A1;US2010249068A1;US2010297079A1;US2010331397A1;US2011020272A1;US2012070411A1;US2012071434A1;US2012165286A1;US2013164261A1;US2013165400A1;US2013252920A1;US2013253181A1;US2013281687A1;EP0371366A1;EP0457326A1;EP2177527A1;EP2166016A1;WO9221343A1;WO9614329A1;WO9816184A2;WO9816186A2;WO9914226A2;WO0034298A1;WO0066604A2;WO02100415A2;WO03026589A2;WO03026675A1;WO03039523A2;WO03070193A2;WO03070912A2;WO03073989A2;WO03102131A2;WO2004002422A2;WO2004002999A2;WO2004003000A2;WO2004014312A2;WO2004046159A1;WO2004052906A1;WO2004062676A1;WO2004080466A1;WO2004106356A1;WO2005000864A1;WO2005020884A2;WO2005021568A2;WO2006000922A2;WO2006094347A1;WO2007005779A2;WO2007020193A2;WO2007038859A1;WO2007038860A2;WO2007113538A1;WO2008005542A2;WO2008043704A1;WO2008043791A2;WO2008071571A1;WO2008083465A1;WO2008086042A2;WO2008089105A2;WO2008095040A2;WO2008100447A2;WO2008117047A1;WO2008121634A2;WO2008124384A2;WO2008125583A1;WO2008125599A1;WO2008136815A2;WO2009009951A1;WO2009025759A1;WO2009040269A1;WO2009064848A1;WO2009067409A1;WO2009069095A2;WO2009080836A2;WO2009085267A1;WO2009086192A1;WO2009086201A1;WO2009102318A1;WO2009120991A2;WO2009132123A1A61K31/70US201113236486BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMARUS8877731B2BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMAR;ALIOS BIOPHARMA INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/20;C07H19/056;C07H19/06;C07H19/10;C07H19/16Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection.20141103US(美国)20150702US8877731B2;US8236779B2C07H19/20US201414531552BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMARUS2015183819A1ALIOS BIOPHARMA INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/06;C07H19/056;C07H19/10;C07H19/16;C07H19/20Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection.20160523US(美国)20160915C07H19/06US201615161821BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMARUS2016264610A1ALIOS BIOPHARMA INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/7115;A61K48/00;A61P3/00;A61P7/04;A61P21/04;A61P25/14;A61P35/00;C07H21/00;C07H21/04;C12N15/10;C12N15/115;C12P19/34;C12Q1/68It is intended to provide a process for producing a functional molecule which shows high affinities for various targets. Namely, a process for producing a functional molecule which involves the step of producing a modified oligonucleotide sequence wherein a modified nucleotide n-mer (n representing an integer) containing a modified nucleoside having a substituent transferred into a nucleoside constituting a nucleic acid is polymerized at random to give the modified oligonucleotide sequence. A preferable embodiment thereof comprises the selection step of selecting a modified nucleotide sequence having an affinity for a target from among the modified nucleotide sequences the sequence-reading out step of amplifying the modified nucleotide sequence thus selected and determining its base sequence and the translation step of translating the sequence of the modified oligonucleotide sequence having the thus determined base sequence based on the relation between at least one of 4<n> nucleotide n-mers and the modified nucleotide n-mer referring to a relation table showing one-to-one combinations of the 4 nucleotides.20030314WO(世界知识产权局)20030925WO9203461A1;WO9640717A1;WO9921873A2;EP1201751A1A61K31/7115WO2003JP03087FUJIHARA TSUYOSHI;FUJITA SHOZO;TAKEISHI SHUNSAKUWO03078623A1FUJITSU LTD;FUJIHARA TSUYOSHI;FUJITA SHOZO;TAKEISHI SHUNSAKU
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/7115;A61K48/00;A61P3/00;A61P7/04;A61P21/04;A61P25/14;A61P35/00;C07H21/00;C07H21/04;C12N15/10;C12N15/115;C12P19/34;C12Q1/68A process for producing a functional molecule includes a forming step which forms a modified nucleotide n-mer (where, n represents an integer) containing a modified nucleoside prepared by introducing a substituent into a nucleoside composing a nucleic acid and a producing step which produces a modified oligonucleotide sequence by randomly polymerizing the modified nucleotide n-mer. A preferable embodiment thereof includes a selecting step which selects a sequence having an affinity to a target from the modified oligonucleotide sequence, a determining step which amplifies the selected modified oligonucleotide sequence and determines the base sequence thereof, and a translating step which translates the sequence of the modified oligonucleotide sequence on the basis of a relation table prepared by relating at least one of 4<SUP>n </SUP>kinds of nucleotide n-mers, which are presented in the relation table prepared by the one-to-one combination of 4 kinds of nucleosides, to a modified nucleotide n-mer.20040917US(美国)20050616US5756291A;US6423493B1;US2002106679A1A61K31/7115US20040943150FUJIHARA TSUYOSHI;FUJITA SHOZO;TAKEISHI SHUNSAKUUS2005130195A1FUJITSU LTD
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/7115;A61K48/00;A61P3/00;A61P7/04;A61P21/04;A61P25/14;A61P35/00;C07H21/00;C07H21/04;C12N15/10;C12N15/115;C12P19/34;C12Q1/68The object of the present invention is to provide a process for producing a functional molecule having a high affinity to various targets. Accordingly, the process for producing the functional molecule includes a producing step which produces a modified oligonucleotide sequence by polymerizing randomly a modified nucleotide n-mer (where, n represents an integer) containing a modified nucleoside prepared by introducing a substituent into a nucleoside composing a nucleic acid. An aspect preferably comprises a selecting step which selects a sequence having an affinity to a target from the modified oligonucleotide sequence, a determining step which amplifies the selected modified oligonucleotide sequence and determines the base sequence thereof, and a translating step which translates the sequence of the modified oligonucleotide sequence, of which base sequence has been determined, on the basis of a relation table prepared by relating at least one of 4<n> kinds of nucleotide n-mers, which are presented in the relation table prepared by the one-to-one combination of 4 kinds of nucleosides, to a modified nucleotide n-mer. <IMAGE>20030314EP(欧洲专利局)20041222WO9205285A1;WO0024404A1;US5756291A;WO9214842A1;WO0023456A1A61K31/7115EP20030708622FUJIHARA TSUYOSHI;FUJITA SHOZO;TAKEISHI SHUNSAKUEP1489171A1FUJITSU LTD
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07D311/36;C07D311/34PURPOSE: A dihydroxychromone derivative is provided to suppress SARS(severe acute respiratory syndrome)-coronavirus helicase activity which causes SARS. CONSTITUTION: A pharmaceutical composition for preventing and treating diseases caused by a coronavirus contains a compound of chemical formula 1 or a pharmaceutically acceptable salt, hydrate or isomer thereof as an active ingredient. The pharmaceutical composition further contains one or more pharmaceutically acceptable carriers, diluents, or excipients. The disease is SARS(severe acute respiratory syndrome). The pharmaceutical composition further contains an antiviral agent. The antiviral agent is a virus serine protease inhibitor, virus polymerase inihibitor, interferone alpha, or ribavirin.20090713KR(韩国)20110120C07D311/36KR20090063550CHONG YOU HOON;JEONG YONG JOO;LEE CHAE WOONKR20110006083AUNIV KONKUK IND COOP CORP
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/404;A61P31/14FIELD: medicine, virology, pharmacy. ^ SUBSTANCE: invention proposes an agent for treatment and prophylaxis of infection caused by coronaviruses, in particular, for treatment of atypical pneumonia (SARS), and pharmaceutical composition of indicated designation based on thereof. Agent represents 1-methyl-2-phenylthiomethyl-3-carbethoxy-4-dimethylaminomethyl-5-oxybromoindole or 1-methyl-2-phenylthiomethyl-3-carbethoxy-4-dimethylaminomethyl-5-oxybromoindole monohydrate hydrochloride (arbidol) known early as an immunomodulator and preparation used against influenza viruses. Invention provides reducing accumulation of coronaviruses (on example with TOPS virus) in lung. ^ EFFECT: valuable medicinal properties of agent. ^ 2 cl, 7 tbl, 9 ex20040421RU(俄罗斯联邦)20050720A61K31/404RU20040111871GLUSHKOV R G;MAKSIMOV V A;MART JANOV V A;KHAMITOV R A;SHUSTER A MRU2256451C1
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/713;A61K38/21;A61P11/00;A61P31/12;A61K31/24;A61K31/4196;A61K31/7088;A61K48/00Avian influenza is treated with natural human alpha interferon, neuraminidase inhibitor(s) and ribavirin. Effects of influenza virus are mitigated with a dsRNA in combination with a neuraminidase influenza virus inhibitor. These two products, dsRNA, and alpha interferon, have therapeutic utility either given preventively (prophylactically) or in treatment of active disease. These unique immunological/antiviral actions, operating through immunological "cascades" ameliorates the lethal effects of viral mutation which, by causing resistance to commonly available drugs, greatly accelerates the death rate.20051108AU(澳大利亚)20051215A61K31/713AU20050229761CARTER WILLIAM A;STRAYER DAVIDAU2005229761A1HEMISPHERX BIOPHARMA
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/073;A61K31/7064;A61P33/06;C07H19/067The present invention includes the utility of anti-viral and/or antibacterial effective amounts of 6-substituted nucleoside derivatives of formula (I) (e.g. 6-iodouridine and 6-iodouridine monophosphate) in the treatment or prevention of viral infections (e.g. Flavivridae, Bunyaviridae, or Togaviridae, or viral infections of hepatitis C, hepatitis B, herpes, influenza, HIV, polio, Coxsackie A/B, rhino, small pox, Ebola, West Nile, or corona virus) and/or bacterial infections (e.g. H. pylori, S. Aureus, B. anthracis, Mycobacterial tuberculosis, M. leprae, M. avium, P. aueruginosa, Streptococcal species, and Pneumocystis carinii).20061003AP(AP)20140331US4873228AC07H19/073AP20080004436BELLO ANGELICA;FUJIHASHI MASAHIRO;KOTRA LAKSHMI PAP2870AUNIV HEALTH NETWORK
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/10;A61K31/7068;A61K31/7072;A61K45/06;C07B59/00;C07H19/06The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya Ebola and West Nile virus), RSV, HEV, and influenza infection and cancer in human subjects or other animal hosts.20151030US(美国)20171123C07H19/10US201515522056COATS STEVEN J;AMBLARD FRANCK;GARNIER-AMBLARD ETHEL;SCHINAZI RAYMOND FUS2017334941A1COCRYSTAL PHARMA INC;UNIV EMORY
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K47/48;C07F9/6512;A61K31/662;A61P3/14;A61P9/08;A61P19/00;A61P19/10;A61P31/00;A61P31/12;A61P35/00;A61P43/00;C07F9/38;C07F9/40;C07F9/6561;C07F9/6574;C07H19/10The present invention relates to phosphonate ester compounds formed by the covalent linking of a phosphonate selected from (a) cidofovir or tenofovir (b) an antiviral nucleoside phosphonate or an antiproliferative nucleoside phosphonate and (c) a derivative of cytosine arabinoside, gemcitabine, 5-fluorodeoxyuridine riboside, 2-chlorodeoxyadenosine, fludarabine or 1-beta-D-arabinofuranoxyl-guanine to an alkylpropanediol. The compounds are used in the preparation of medicaments for treating a viral disease in a subject in need thereof, wherein said viral disease is selected from the human immunodeficiency virus, influenza, the herpes simplex virus, the human herpes virus, the cytomegalovirus, the hepatitis B and C virus, the Epstein-Barr virus, the varicella zoster virus, the orthopox virus, the ebola virus and the papilloma virus.20001204EP(欧洲专利局)20080423EP0632048A1;WO9838202A1;EP0479640A2A61K47/48EP20080001408HOSTETLER KARL Y;KINI GANESH D;BEADLE JAMES REP1914237A2UNIV CALIFORNIA AT SAN DIEGO
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/7042;A61K31/7072;A61K31/513;A61P31/00;A61P31/04;A61P31/06;A61P31/14;A61P31/16;A61P31/18The present invention includes the utility of anti-viral and/or antibacterial effective amounts of 6-substituted nucleoside derivatives of formula (I) (e.g. 6-iodouridine and 6-iodouridine monophosphate) in the treatment or prevention of viral infections (e.g. Flavivridae, Bunyaviridae, or Togaviridae, or viral infections of hepatitis C, hepatitis B, herpes, influenza, HIV, polio, Coxsackie A/B, rhino, small pox, Ebola, West Nile, or corona virus) and/or bacterial infections (e.g. H. pylori, S. Aureus, B. anthracis, Mycobacterial tuberculosis, M. leprae, M. avium, P. aueruginosa, Streptococcal species, and Pneumocystis carinii).20061003US(美国)20100408A61K31/7042US20060089100KOTRA LAKSHMI P;PAI EMIL FUS2010087388A1KOTRA LAKSHMI P;PAI EMIL F
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/073;A61K31/7064;A61P33/06;C07H19/067The present invention includes the utility of anti-viral and/or antibacterial effective amounts of 6-substituted nucleoside derivatives of formula (I) (e.g. 6-iodouridine and 6-iodouridine monophosphate) in the treatment or prevention of viral infections (e.g. Flavivridae, Bunyaviridae, or Togaviridae, or viral infections of hepatitis C, hepatitis B, herpes, influenza, HIV, polio, Coxsackie A/B, rhino, small pox, Ebola, West Nile, or corona virus) and/or bacterial infections (e.g. H. pylori, S. Aureus, B. anthracis, Mycobacterial tuberculosis, M. leprae, M. avium, P. aueruginosa, Streptococcal species, and Pneumocystis carinii).20061003EP(欧洲专利局)20080618C07H19/073EP20060790781KOTRA LAKSHMI P;PAI EMIL F;BELLO ANGELICA M;FUJIHASHI MASAHIROEP1931691A1UNIV HEALTH NETWORK
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/173;A61K31/7052;A61K31/706;A61K31/7076;A61K31/708;A61P31/12;A61P31/18;A61P31/20;A61P35/00;C07H19/04;C07H19/23The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs may show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tautomerism and mutagenesis of the nucleoside analogs may be adjusted by substituting the nucleoside analogs with one or more electron-donating groups and/or electron-withdrawing groups to increase or decrease the pK a (e.g., to a pK a between 5.5 or 8.5). The present disclosure also provides pharmaceutical compositions and kits including the nucleoside analogs and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis) or cancer using the nucleoside analogs, pharmaceutical compositions, or kits.20160128WO(世界知识产权局)20160804US2014206639A1C07H19/173WO2016US15456ESSIGMANN JOHN M;TOKMAKOFF ANDREI;FEDELES BOGDAN I;SINGH VIPENDER;PENG CHUNTEWO2016123397A2MASSACHUSETTS INST TECHNOLOGY
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/12;C12Q1/68;G01N21/3577;G01N33/15The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs are expected to show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tautomerism and mutagenesis of the nucleoside analogs may be adjusted by substituting the nucleoside analogs with one or more electron-donating groups and/or electron-withdrawing groups to increase or decrease the pKa (e.g., to a pKa between 5.5 or 8.5). The present disclosure also provides pharmaceutical compositions and kits including the nucleoside analogs and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis) or cancer using the nucleoside analogs, pharmaceutical compositions, or kits.20160128US(美国)20160804C07H19/12US201615009628ESSIGMANN JOHN M;TOKMAKOFF ANDREI;FEDELES BOGDAN I;SINGH VIPENDER;PENG CHUNTEUS2016222050A1MASSACHUSETTS INST TECHNOLOGY
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/12;A61K31/7052;A61K31/706;A61K31/7064;A61K31/7068;A61K31/7076;A61K31/708;C07H19/04;C07H19/173;C07H19/23;C12Q1/68;G01N21/3577;G01N33/15The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs are expected to show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tautomerism and mutagenesis of the nucleoside analogs may be adjusted by substituting the nucleoside analogs with one or more electron-donating groups and/or electron-withdrawing groups to increase or decrease the pKa (e.g., to a pKa between 5.5 or 8.5). The present disclosure also provides pharmaceutical compositions and kits including the nucleoside analogs and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis) or cancer using the nucleoside analogs, pharmaceutical compositions, or kits.20170706US(美国)20171102C07H19/12US201715642402ESSIGMANN JOHN M;TOKMAKOFF ANDREI;FEDELES BOGDAN I;SINGH VIPENDER;PENG CHUNTEUS2017313736A1MASSACHUSETTS INST TECHNOLOGY
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/10;A61K9/00;A61K9/14;A61K31/7072;A61K45/06;C07H19/06The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV, HEV, and influenza infection and cancer in human subjects or other animal hosts.20160427US(美国)20170817C07H19/10US201615139924COATS STEVEN J;AMBLARD FRANCK;MENGSHETTI SEEMA;LI HAO;SCHINAZI RAYMOND FUS2017233428A1COCRYSTAL PHARMA INC;UNIV EMORY
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/06;A61K31/7068;A61K31/7076;A61P31/12;A61P31/16;A61P35/00;C07H19/16The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV and influenza infection and cancer in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.20150424WO(世界知识产权局)20151029WO2008121634A2;WO2010080878A1C07H19/06WO2015US27630COATS STEVEN J;ZHOU SHAOMAN;AMBLARD FRANCK;SCHINAZI RAYMOND F;KHALIL AHMEDWO2015164812A1COCRYSTAL PHARMA INC;UNIV EMORY
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/207;A61K31/706;A61K31/7068;A61K31/7072;A61K31/7076;A61K45/06;C07H19/10;C07H19/12;C07H19/14The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV and influenza infection and cancer in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.20150424US(美国)20170209C07H19/207US201515305287COATS STEVEN J;ZHOU SHAOMAN;AMBLARD FRANCK;SCHINAZI RAYMOND F;KHALIL AHMEDUS2017037078A1COCRYSTAL PHARMA INC;UNIV EMORY
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/10;A61K31/712;A61K38/21;A61P31/12;A61P35/00;C07H19/067;C07H19/167;C07H19/20The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya Ebola and West Nile virus), RSV, HEV, and influenza infection and cancer in human subjects or other animal hosts.20151030WO(世界知识产权局)20160506WO2013009735A1;WO2009132123A1;WO2005012327A2;US2012070411A1;WO2015081297A1;WO2015081133A2;WO2015056213A1C07H19/10WO2015US58194COATS STEVEN J;AMBLARD FRANCK;GARNIER-AMBLARD ETHEL;SCHINAZI RAYMOND FWO2016069975A1COCRYSTAL PHARMA INC;UNIV EMORY
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/056;A61K31/7056;A61P31/22FIELD: biotechnology.SUBSTANCE: invention relates to new antiviral derivatives of general formula:,where R is selected from H, CH, CH(CH), Ph, as well as to a process for their preparation that can be used in the pharmaceutical industry. The proposed production method involves introduction of isopropylidene and triphenylmethyl protecting groups into the glycosidic portion of ribavirin, dehydration of the carboxamide group into amidoxime, preparation of an O-acylated derivative with an amidoxime moiety followed by intramolecular cyclization to obtain a glycosidically protected ribavirin analogue having a 5-substituted-1,2,4-oxadiazole fragment at the 3rd position of 1,2,4-triazole, and subsequent removal of the isopropylidene and trimethylphenyl protecting groups.EFFECT: new compounds effective against herpes simplex virus type 1, influenza A virus and hepatitis C virus, as well as an effective way of their preparation, are proposed.3 cl, 12 ex, 6 dwg20161208RU(俄罗斯联邦)20170829C07H19/056RU20160148156CHUDINOV MIKHAIL VASILEVICH;ZHURILO NIKOLAJ ILICH;MATVEEV ANDREJ VALEREVICHRU2629360C1FED GOSUDARSTVENNOE BYUDZHETNOE OBRAZOVATELNOE UCHREZHDENIE VYSSHEGO OBRAZOVANIYA MOSKOVSKIJ TEKH UN
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/14;A61K31/21;A61K31/216;A61P31/00;A61P31/12The use of a compound of general formula (1) in the treatment of diseases caused by viral <EMI ID=1.1 HE=98 WI=122 LX=430 LY=820 TI=CF> <PC>infection. Examples of such anti-viral agents are Benzeneacetic acid 2-(diethylamino)ethyl ester (2) and 2-(Diethylamino)ethyl-2-phenylethanoate (3). These anti-viral agents may be used on their own or they may be used in combination with other anti-viral agents, such as ribavirin. It may also be administered in combination with other agents that reduce possible side-effects during treatment. It may be administered as a tablet or as an infusion. Compounds (2) and (3) were shown to have an effect on the growth of influenza A virus in MDCK cells.19990318GB(英国)20000920EP0763754A2A61K31/14GB19990006211GARNETT DAVID JOHNGB2347858ALOVESGROVE RES LTD
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/7076;A61K31/708;A61K31/7084;A61K31/7088PURPOSE: A base, a nucleoside, or a nucleotide effectively is provided to suppress virus replication with less side effects and to be used as an antiviral pharmaceutical composition. CONSTITUTION: An antiviral pharmaceutical composition contains one or more selected from the group consisting of adenine, guanine, uracil, cytosine, adenosine, guanosine, uridine, cytidine, adenosine biphosphate, and adenosine triphosphate. Rhinovirus is selected among rhinovirus type 2, 3, 14, 15, and 40. Enterovirus is enterovirus type 71. A pharmaceutical composition for anti-influenza virus contains adenosine and/or adenine as active ingredients. The influenza virus is influenza virus type A.20111122KR(韩国)20130530US4046879A;EP1000622A2;KR20040054775AA61K31/7076KR20110122550KWON DUR HAN;SONG JAE HYUNG;OH SEI RYANG;LEE HYEONG KYU;EUKHTAIVAN GANSUKHKR20130056784AKOREA RES INST OF BIOSCIENCE
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/405;A61K31/13;A61K31/196;A61K31/215;A61K31/351;A61K31/7056;A61P31/12The invention relates to medicine, in particular to searching and developing novel medicinal agents for treating and preventing viral infections, mainly influenza viruses. The aim of said invention is to develop more efficient and low toxic medicinal agents by combining arbidol and the analogs thereof with a preparation exhibiting another mechanism of action. Said combinations enhances the efficiency of the preparation small doses and makes it possible to reduce the probability of side effects and appearance of virus resistant strain by reducing the dose. The result is attained by the combined use of arbidol and the analogies thereof with at least one type of preparation selected from the following group of antiviral preparations: ribavirin, zanamivirin, oseltavirin, peramirin, amantadin or remantadin.20051228WO(世界知识产权局)20070705RU2008004C1;RU2262350C2;US2004062801A1A61K31/405WO2005RU00677LENEVA IRINA ANATOLIEVNAWO2007075102A1ZAKRYTOE AKTSIONERNOE OBSCHEST;LENEVA IRINA ANATOLIEVNA
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/7056;A61K38/21;A61P31/14The invention relates to antimicrobial agents and antibodies and compositions comprising such agents and antibodies to treat and/or prevent respiratory and related diseases, in particular those caused by human metapneumovirus. Provided is a method for treating or preventing respiratory tract infections in a subject infected with a mammalian MPV, said method comprising administering a nucleoside analog, preferably Ribavirin or a derivative thereof, and an antimicrobial neutralising antibody, preferably an anti-hMPV antibody to said subject, and use of said nucleoside analog and antimicrobial neutralising antibody for the manufacture of a medicament for treating or preventing respiratory tract infections in a subject infected with a mammalian MPV.20040503WO(世界知识产权局)20041111WO02057302A2A61K31/7056WO2004NL00293MAERTZDORF JEROEN;SIMON JAMES HENRY MATTHEWWO2004096241A1VIRONOVATIVE BV;MAERTZDORF JEROEN;SIMON JAMES HENRY MATTHEW
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/4745Methods to stimulate host immune system against viral infections are disclosed. Methods to stimulate immune response of a virally, influenza or cancer infected individual through an immunomodifier such as a non-nucleoside imidazoquinolinamine (heterocyclic amine) are disclosed.20060419WO(世界知识产权局)20061026US2004136917A1;US2004067953A1A61K31/4745WO2006US14803MANDREA EUGENEWO2006113835A2MANDREA EUGENE
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/4745Methods to stimulate host immune system against viral infections are disclosed. Methods to stimulate immune response of a virally, influenza or cancer infected individual through an immunomodifier such as a non-nucleoside imidazoquinolinamine (heterocyclic amine) are disclosed.20051221US(美国)20060817US6039969A;US6361769B1;US2004067953A1;US6569435B1;US6890904B1;US6245776B1;US6576757B1;US2003139364A1;US2004136917A1;US3608065A;US6147086A;US6491940B1A61K31/4745US20050318659MANDREA EUGENEUS2006183767A1MANDREA EUGENE
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K9/12;A61K31/708;A61K38/44The present invention is a novel method using a MegaRibavirin aerosol or a MegaRibavirin combination of therapeutics for the treatment of viral disease particularly the pandemic influenza strains ??swine?? 2009 H1N1 and H5N1. This invention utilizes Ribavirin in an aerosol Mega Dose (61-161 mg/ml) alone or combined with or without other antivirals, a perfluorocarbon emulsion and anti-inflammatory/anti-oxidants. Where applicable, the perfluorocarbon emulsion may dissolve these agents enabling a depot effect and possible protracted delivery. In addition perfluorocarbon emulsions have the possible added benefit of oxygen carrying capacity and alveolar nitric oxide sequestration, which may reduce peroxynitrite formation and decrease Influenza severity.20090521US(美国)20101125US4649911A;US2006134186A1;US5049388AA61K9/12US20090454663MCLEAY MATTHEW TUS2010297033A1MCLEAY MATTHEW T
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/352;A61P31/12;A61P31/16;A61P31/22<P>PROBLEM TO BE SOLVED: To provide an antiviral agent which has a high antiviral activity against a drug-resistance virus having resistance characteristics to well-known antiviral agents (such as Oseltamivir, Amantadine, Ganciclovir, etc.) and has a low side effect (cell toxicity). <P>SOLUTION: The antiviral agent against the drug-resistance virus includes tricine 5,7,4'-trihydroxy-3',5'-dimethoxyflavone(4',5,7-trihydroxy-3',5'-dimethoxyflavone)(tricin) as the effective component. Preferably, the drug-resistance virus is influenza virus, cytomegalovirus, or herpesvirus. <P>COPYRIGHT: (C)2011,JPO&INPIT20090428JP(日本)20101111WO2008123102A1A61K31/352JP20090109646MURAYAMA TSUGIYA;AKUZAWA KAZUHIKO;WATANABE KUNITOMO;KOKETSU MAMORU;NINOMIYA MASAYUKI;TSUCHIDA YUZO;TSUCHIDA KOTARO;SAKURAI DAISUKE;KAWABE MITSURO;ONOGI MANABUJP2010254649ATSUCHIDA YUZO
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07D473/00;C12N7/00The novel nucleoside analogue 9-1-(1,3-diacetoxy-2-propoxy)-2-acetoxyethylguanine has the effect of stimulating the rate of growth of certain viruses, particularly influenza viruses, so that culturing virally infected cells in the presence of this compound substantially decreases the time required for diagnosis and typing of the virus, ready for administration of appropriate anti viral measures.19830218US(美国)19840717US4347360AC07D473/00US19830467900OGILVIE KELVIN KUS4460690AENS BIO LOGICALS INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/207;C07H19/06The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds.20150206WO(世界知识产权局)20150813C07H19/207WO2015US14762SMITH MARK;KLUMPP KLAUS GWO2015120237A2RIBOSCIENCE LLC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H19/207;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61K45/06;C07H19/06;C07H19/10;C07H19/16The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds.20150206US(美国)20150813US2015011497A1C07H19/207US201514615928SMITH MARK;KLUMPP KLAUS GUS2015225441A1RIBOSCIENCE LLC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07H7/06;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61K45/06;C07H19/06;C07H19/10;C07H19/16;C07H19/213The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds.20160620US(美国)20181009US9370569B2;US2015011497A1;US5192749A;US7105499B2;US2003087873A1;US2004229840A1;US2010003213A1;US2013165400A1;US2013243725A1;US2013315868A1;US2014178338A1;US2014179627A1;US2014179910A1;US2015051167A1;WO2012037038A1;WO2012040124A1;WO2013096679A1;WO2013138236A1;WO2014100505A1;WO2014209979A1;WO2015054465A1C07H7/06US201615187014SMITH MARK;KLUMPP KLAUS GUS10092649B2RIBOSCIENCE LLC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07D473/18;A61K31/513;A61K31/52;A61K31/522;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61P3/12;A61P31/12;A61P35/00;A61P35/02;C07D405/04;C07D473/30;C07D473/34;C07H19/048;C07H19/06;C07H19/067;C07H19/10;C07H19/16;C07H19/167;C07H19/20;C07H21/04;C12Q1/68The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction ("RT-PCR"). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.20011018US(美国)20030508US5886162A;US5512671A;US4666892A;US5905070A;US2004110718A1;US4211773A;US5034518A;US5446029A;US5246924A;US5808040A;US5565438A;US5567688A;US6812219B2;US5587362A;US5703058A;US7307065B2C07D473/18US20010045292STUYVER LIEVEN;WATANABE KYOICHIUS2003087873A1
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/7076;C07D473/18;A61K31/513;A61K31/52;A61K31/522;A61K31/7064;A61K31/7068;A61K31/7072;A61K31/708;A61P3/12;A61P31/12;A61P31/14;A61P35/00;A61P35/02;C07D405/04;C07D473/30;C07D473/34;C07H19/048;C07H19/06;C07H19/067;C07H19/10;C07H19/16;C07H19/167;C07H19/20;C07H21/04;C12Q1/68The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (??RT-PCR??). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.20100805US(美国)20111103US6812219B2A61K31/7076US20100805563STUYVER LIEVEN;WATANABE KYOICHIUS2011269707A1PHARMASSET INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07D473/18;A61K31/513;A61K31/52;A61K31/522;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61P3/12;A61P31/12;A61P35/00;A61P35/02;C07D405/04;C07D473/30;C07D473/34;C07H19/048;C07H19/06;C07H19/067;C07H19/10;C07H19/16;C07H19/167;C07H19/20;C07H21/04;C12Q1/68CANRPonb\DCC\KXG\4371196_ LDOC-416/2"12 The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of 5 general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction ("TR-PCR"). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.20120604AU(澳大利亚)20120621C07D473/18AU20120203287STUYVER LIEVEN;WATANABE KYOICHI AAU2012203287A1PHARMASSET INC
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07D473/18;A61K31/513;A61K31/52;A61K31/522;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61P3/12;A61P31/12;A61P35/00;A61P35/02;C07D405/04;C07D473/30;C07D473/34;C07H19/048;C07H19/06;C07H19/067;C07H19/10;C07H19/16;C07H19/167;C07H19/20;C07H21/04;C12Q1/68The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction ("TR-PCR"). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.20011018WO(世界知识产权局)20040219WO9818324A1;WO0160315A2;WO0218404A2C07D473/18WO2001US46113STUYVER LIEVEN;WATANABE KYOICHI AWO0232920A3PHARMASSET LTD;STUYVER LIEVEN;WATANABE KYOICHI A
治疗用药 -> 化学药 -> 抑制病毒核酸复制A61K31/40;A61K31/403;A61K31/404;A61P31/12;A61P37/00;A61P37/04;A61P43/00;C07D209/42A new substance is disclosed: ethyl ester-6-bromine-5-hydroxy-4-dimethylaminomethyl-1-methyl-2-phenylthiom ethyl indole-3-carboxylic acid hydrochloride monohydrate has formula (I). A method of obtaining said substance consists in treating the ethyl ester 5-acetoxy-1,2-dimethyl indole-3-carboxylic acid with a bromating agent in the medium of an inert organic solvent at boiling temperature, subjecting the obtained ethyl ester 5-acetoxy-6-bromine-2-bromo-methyl-1-methyl indole-3-carboxylic acid to interaction with thiophenol in the presence of a hydroxide of an alkaline metal or its alcoholate in the medium of an organic solvent, subjecting the obtained ethyl ester 6-bromine-5-hydroxy-1-methyl-2-phenylthiomethyl indole-3-carboxylic acid to interaction with an aminomethylating agent in the medium of an organic solvent at a temperature from 65 DEG C to the boiling point of the reaction mixture. Then the desired product is extracted from the obtained base, the ethyl ester 6-bromine-5-hydroxy-4-dimethylaminomethyl-1-methyl-2-phenylthiomethyl indole-3-carboxylic acid. The claimed substance is an active agent in a pharmaceutical preparation of antiviral, interferon inducing and immunomodulating action.19890112WO(世界知识产权局)19900726WO8805432A1;US4619942A;US4215137A;US4124702A;WO8706227A2A61K31/40WO1988SU00272TROFIMOV FEDOR ALEXANDROVICH;TSYSHKOVA NINA GAVRILOVNA;BOGDANOVA NADEZHDA SERGEEVNA;NIKOLAEVA IRINA SERGEEVNA;ZOTOVA SVETLANA ALEXEEVNA;SAKHASCHIK ZINAIDA MIKHAILOVNA;SVIRINA EVGENIA ALEXANDROVNA;FOMINA ALLA NIKOLAEVNA;PADEISKAYA ELENA NIKOLAEVNA;ZLYDNIKOV DMITRY MIKHAILOVICH;KUBAR OLGA IOSIFOVNA;SHVETSOVA EVGENIA GEORGIEVNA;BRYANTSEVA ELENA ALEXEEVNA;PETERS VALENTINA VASILIEVNA;KUTCHAK SVETLANA NIKOLAEVNA;KONOPLYANNIKOV ANATOLY GEORGIEWO9008135A1GRINEVA GALINA VASILIEVNA & LF;PERSHINA ELLINA GRIGORIEVNA &;VNI KHIM FARMATS;NII MED RADI;LE NII EPID
治疗用药 -> 化学药 -> 抑制病毒核酸复制C07D309/10;C07H19/00Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (I): wherein the 1 ' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.20110722WO(世界知识产权局)20120126WO2009132135A1;WO2010002877A2;WO2008141079A1;WO2008089105A2;WO0056734A1;US4816570A;US4968788A;US5663159A;US5792756A;WO9119721A1;US6312662B1;US5458135A;US5740794A;US5775320A;US5785049A;US3906950A;US4013075A;US4069819A;US4995385A;US5522385A;US4668218A;US4667668A;US4805811A;US5388572A;US5261538A;US5544647A;US5622163A;US4955371A;US3565070A;US3361306A;US6116234AC07D309/10WO2011US45102MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNESWO2012012776A1GILEAD SCIENCES INC;MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/472;A61P31/12;C07D217/26It is intended to provide an anti-coronavirus drug containing as the active ingredient a compound typified by nelfinavir or its pharmaceutically acceptable salt an anti-SARS drug containing the anti-coronavirus drug as the active ingredient and a method of treating SARS by using the anti-SARS drug.20040714WO(世界知识产权局)20050120JPH0950143AA61K31/472WO2004JP10352FUJII NOBUTAKA;YAMAMOTO NAOKIWO2005004868A1FUJII NOBUTAKA;YAMAMOTO NAOKI
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/472;A61P31/12;C07D217/26The present invention provides an anti-coronavirus agent including as an active ingredient as exemplified by nelfinavir and salts thereof, an anti-SARS agent including the anti-coronavirus agent, and a method of treating SARS using the anti-SARS agent.20040714EP(欧洲专利局)20060503WO2004108151A1;WO02089835A2A61K31/472EP20040747768FUJII NOBUTAKA;YAMAMOTO NAOKIEP1652525A1ARIGEN INC
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/47;A61K31/426;A61K31/505;A61P31/18The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-(2S)-1-hydroxy-3-methylbutan-2-yl-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof.20080626UAA(UAA)20131210A61K31/47UAA200913904KEARNEY BRIAN P;MATHIAS ANITA AUA103881C2GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07D403/12;A61K31/337;A61K31/4155;A61K31/495;A61K31/504;A61K31/506;A61K31/5365;C07C243/28;C07C275/16;C07D401/12;C07D405/14;C07D471/08;C07D487/08;C07D487/10;C07D491/04The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, the compound of formula (I) for use in therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I. Preferred compounds are N-[(2S) -1-[2-[(2S,3S)-2-hydroxy-3-[(2S)-2-(methoxycarbonylamino) -3,3-dimethylbutanoylamino]-4-phenylbutyl]-2-(phenyl) methylhydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate atazanavir (ATV) analogues substituted by several heterocycles, such as e.g. pyrazole (Rl) e.g. oxetane (substituent of X2) e.g. pyridine or pyrimidine (X1) e.g. piperazine or 3,8-diazabicyclo3.2.1octan (X2).20180205WO(世界知识产权局)20180809C07D403/12WO2018US16893BACON ELIZABETH M;CHIN ELBERT;COTTELL JEROMY J;KATANA ASHLEY ANNE;KATO DARRYL;LINK JOHN O;SHAPIRO NATHAN;TREJO MARTIN TERESA ALEJANDRA;YANG ZHENG-YUWO2018145021A1GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/426;A61K31/47;A61P31/18The invention provides methods for improving the pharmacokinetics of an HIV integrase inhibiting compound by administering food and/or ritonavir or a pharmaceutically acceptable salt thereof with the HIV integrase inhibitor.20061229WO(世界知识产权局)20070712WO2004067531A1;WO2004101512A2;EP1564210A1;WO2005112930A1;WO2005113508A1;US6541515B2;WO9414436A1;US5567823A;US5541206A;US5635523A;US5648497A;US5674882A;US5846987A;US5886036A;US6037157A;US6703403B2;US2005239819A1;US2004167124A1;US2005288326A1A61K31/426WO2006US49668KEARNEY BRIAN P;KAKEE ATSUYUKI;KAWAGUCHI ISAOWO2007079260A1GILEAD SCIENCES INC;JAPAN TOBACCO INC;KEARNEY BRIAN P;KAKEE ATSUYUKI;KAWAGUCHI ISAO
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/675;A61K31/513;A61K31/5377;A61K31/635;A61P31/18The disclosure is directed to methods of treating subjects infected with HIV, once daily, with single unit dosage forms that include darunavir (or a hydrate or solvate thereof), cobicistat, emtricitabine, and a tenofovir prodrug, or salt thereof.20180719US(美国)20190124A61K31/675US201816040324BOVEN KATIA;DE SMEDT GOEDELE;DRIESEN REGINA;HENRIST DOMINIEK;KAUWENBERGHS GREET;MATHUR SANDEEP;MCCALLISTER SCOTT;MERTENS ROEL;NETTLES RICHARD;OPSOMER MAGDA;PYRZ WILLIAM;ZIA VAHIDUS2019022113A1JANSSEN SCIENCES IRELAND UC;GILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/47The invention provides methods for improving the pharmacokinetics of an HIV integrase inhibiting compound by administering food and/or ritonavir or a pharmaceutically acceptable salt thereof with the HIV integrase inhibitor.20061229US(美国)20090917US2006019906A1;US2006030710A1;US7176220B2;US5886036A;US6037157A;US6703403B2;US2002045658A1;US6541515B2;US5635823A;US6407128B1;US5541206A;US5648497A;US2004167124A1;US2006217413A1;US2007219243A1;US5567523A;US5674882A;US2005239819A1;US5846987A;US2005288326A1;US7635704B2A61K31/47US20060097859KEARNEY BRIAN P;KAKEE ATSUYUKI;KAWAGUCHI ISAOUS2009233964A1GILEAD SCIENCES INC;JAPAN TOBACCO INC
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07D417/14;A61K31/427;A61P31/12;C07D277/24;C07D277/28;C07D295/13;C07D295/15Disclosed is a pharmaceutical composition comprising cobicistat / GS-9350 (as represented by formula IIBa) or a pharmaceutically acceptable salt thereof, in combination with two or three additional therapeutic agents selected from the group consisting of tenofovir disoproxil fumarate, emtricitabine, elvitegravir, efavirenz, atazanavir, darunavir, raltegravir, rilpivirine, and tenofovir alafenamide fumarate (GS-7340) wherein the compound of formula IIBa or pharmaceutically acceptable salt thereof is not in combination with tenofovir disoproxil fumarate, emtricitabine and elvitegravir, for treating an HIV infection or HCV infection in a human patient. Also disclosed is the use of cobicistat / GS-9350 (as represented by formula IIBa) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving the pharmacokinetics of two or three additional therapeutic agents which are metabolized by cytochrome P450 monooxygenase or increasing the blood plasma level of the added therapeutic agents which are metabolized by cytochrome P450 monooxygenase, wherein the medicament is formulated for simultaneous, sequential or separate administration with a combination of said two or three additional therapeutic agents selected from the group consisting of tenofovir disoproxil fumarate, emtricitabine, elvitegravir, efavirenz, atazanavir, darunavir, raltegravir, rilpivirine, and GS-7340 wherein the combination of two or three additional therapeutic agents is not tenofovir disoproxil fumarate, emtricitabine and elvitegravir.20080222NZ(新西兰)20150828C07D417/14NZ20080612093LIU HONGTAO;DESAI MANOJ C;HONG ALLEN Y;VIVIAN RADALL W;XU LIANHONG;HUI HON CNZ612093AGILEAD SCIENCES INC
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/426;A61K31/47;A61P31/18The invention provides methods for improving the pharmacokinetics of an HIV integrase inhibiting compound by administering food and/or ritonavir or a pharmaceutically acceptable salt thereof with the HIV integrase inhibitor.20061229EP(欧洲专利局)20110413WO2004067531A1;WO2004101512A2;EP1564210A1;WO2005112930A1;WO2005113508A1;WO9414436A1;US5567823A;US5541206A;US5635523A;US5648497A;US5674882A;US5846987A;US5886036A;US6037157A;US6703403B2;US49283303A;US2005239819A1;US2004167124A1;US34630506A;US2005288326A1A61K31/426EP20100193364KEARNEY BRIAN P;KAKEE ATSUYUKI;KAWAGUCHI ISAOEP2308490A1GILEAD SCIENCES INC;JAPAN TOBACCO INC
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/426;A61K31/47;A61P31/18The invention provides methods for improving the pharmacokinetics of an HIV integrase inhibiting compound by administering food and/or ritonavir or a pharmaceutically acceptable salt thereof with the HIV integrase inhibitor.20061229EP(欧洲专利局)20081008A61K31/426EP20060848393KEARNEY BRIAN P;KAKEE ATSUYUKI;KAWAGUCHI ISAOEP1976517A1GILEAD SCIENCES INC;JAPAN TOBACCO INC
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/5377;A61K9/20;A61K9/24;A61K31/4418Formulations of the HIV compounds atazanavir and cobicistat, and methods of treatment utilizing these formulations, are set forth.20141006US(美国)20160211US8461129B2;US6579851B2;US2013041004A1;US2013084243A1;US2013096073A1;US2011028412A1;US5558071A;WO2011127244A2A61K31/5377US201414425443KOO OTILIA MAY YUE;NIKFAR FARANAK;TAO JING;KOTTALA NIRANJAN KUMAR;VARIA SAILESH AUS2016038502A1SQUIBB BRISTOL MYERS CO
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/513;A61K9/14;A61K9/20;A61K9/48;A61K31/427;A61K47/02;A61P31/18The invention relates to the field of the chemical and pharmaceutical industry. The present pharmaceutical composition exhibiting activity against HIV infection comprises lopinavir and ritonavir in an effective amount, and an aluminometasilicate. A solid, finished dosage form can be in the form of powders, tablets, combination tablets, capsules, dragees, or granules, covered with a shell, a suppository, or powders for producing suspensions. The dosage forms can be made according to a traditional method. The invention makes it possible to broaden the range of pharmaceutical compositions exhibiting antiviral activity and to improve their pharmacokinetic properties.20180615WO(世界知识产权局)20190103A61K31/513WO2018RU00396KHAZANOVA ELENA SERGEEVNA;NOGAI SERGEI UREVICH;YAKOVLEV DMITRY VLADIMIROVICHWO2019004871A1LLC IZVARINO PHARMA
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/513;A61K9/20;A61K31/427;A61K47/32;A61K47/34;A61P31/18The invention relates to the field of the pharmaceutical chemical industry. The present pharmaceutical composition for treating HIV infection comprises lopinavir and ritonavir in an effective amount, and a polymer. The pharmaceutical composition is produced by extrusion. The composition comprises, as the polymer, a matrix polymer consisting of PEG 6000 / vinylcaprolactam / vinyl acetate, at 5 to 25 % of the mass of the pharmaceutical composition, in combination with copovidone, at 45 to 65 % of the mass of the pharmaceutical composition. This invention makes it possible to broaden the range of available drugs with improved pharmacokinetic properties.20170825WO(世界知识产权局)20180329EA011924B1;US2016193151A1;US2013190337A1A61K31/513WO2017RU00622KHAZANOVA ELENA SERGEEVNA;NOGAI SERGEI UREVICH;IAKOVLEV DMITRII VLADIMIROVICHWO2018056865A1LLC IZVARINO PHARMA
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/00The present invention relates to stable amorphous form of a HIV protease inhibitor, namely, Atazanavir. The present invention preferably relates to stable amorphous form of Atazanavir free base. The present invention also relates to an improved process for the preparation of Atazanavir sulfate from amorphous Atazanavir free base. The present invention also relates to solid dispersion/premix comprising amorphous Atazanavir free base and a pharmaceutically acceptable excipient.20160909WO(世界知识产权局)20170316US8461347B2;WO2014125270A1A61K31/00WO2016IB55393VETUKURI PRASADA RAJU VNKV;GILLA GOVERDHAN;VEDANTHAM RAVINDRA;KAMMA YUVASAI KRISHNA;CHIGURUPATI KRISHNA PRASADWO2017042735A1GRANULES INDIA LTD;VETUKURI PRASADA RAJU VNKV;GILLA GOVERDHAN;VEDANTHAM RAVINDRA;KAMMA YUVASAI KRISHNA;CHIGURUPATI KRISHNA PRASAD
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07D491/147;A61K31/513;A61K31/519;A61P31/12;A61P31/14;C07D239/10;C07H19/073The invention relates to the field of organic chemistry and medicine, and more particularly to synthetic substances of the pyrimidine series, namely 2-chloro-5-phenyl-5H-pyrimido5',4':5,6pyrano2,3-dpyrimidine-4-ol derivatives, having antiviral activity. Claimed are a drug with antiviral activity against HIV infection and hepatitis B virus, containing 2-chloro-5-phenyl-5H-pyrimido5',4':5,6pyrano2,3-dpyrimidine-4-ol derivatives of the general formula shown, where: X is selected from the group: Н, NO2, Hal, ОМе R1 is selected from the group: Сl, ОН and R2 is selected from the group: Cl, SH, ОН and a drug with antiviral activity against HIV infection, containing a 2-chloro-5-phenyl-5H-pyrimido5',4':5,6pyrano2,3-dpyrimidine-4-ol derivative of the general formula shown, where: X is selected from the group: Н, NO2, Hal, ОМе R1 is selected from the group: Cl, ОН and R2 is selected from the group: Cl, SH, ОН in combination with a reverse transcriptase inhibitor selected from Retrovir, or in combination with a protease inhibitor selected from Lopinavir, in an effective amount. The result is an effective drug with antiviral activity.20160406WO(世界知识产权局)20161006RU2188201C2;RU2246496C1;US4578380AC07D491/147WO2016RU00197TETS VIKTOR VENIAMINOVICH;TETS GEORGY VIKTOROVICH;KRASNOV KONSTANTIN ANDREEVICHWO2016159836A1TETS VIKTOR VENIAMINOVICH;TETS GEORGY VIKTOROVICH
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/381;A61K31/4402;A61P31/18The present invention provides a method of treating HIV-1 infection in a subject. The method comprises administering to the subject a combination of anti-HIV-1 agents wherein the combination comprises an effective dose of Apricitabine and an effective dose of Atazanavir.20121115WO(世界知识产权局)20130523US2009162319A1;WO2005082362A1A61K31/381WO2012AU01409COATES JONATHAN ALAN VICTOR;COX SUSAN WENDYWO2013071353A1AVEXA LTD;COATES JONATHAN ALAN VICTOR;COX SUSAN WENDY
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/34;A61K31/426;A61K31/4418;A61K31/505;A61K31/513;A61K31/52;A61K31/536;A61K31/661;A61K31/675;A61K31/7068;A61P31/18The invention relates to a pharmaceutical composition for treating the human immunodeficiency virus (HIV) in humans, including three or four active principles selected as: a nucleoside reverse transcriptase inhibitor (NARTI) selected from lamivudine and emtricitabine a nucleoside or nucleotide reverse transcriptase inhibitor (NARTI) selected from didanosine, abacavir and tenofovir and the combination of ritonavir with a protease inhibitor (PI) selected from lopinavir, fosamprenavir, atazanavir and darunavir or an non-nucleoside reverse transcriptase inhibitor (NNRTI) selected from efavirenz and etravirine for daily administration to said human being one to four days per week.20101119WO(世界知识产权局)20110526A61K31/34WO2010EP67851LEIBOWITCH JACQUESWO2011061302A1ASSIST PUBL HOPITAUX DE PARIS;LEIBOWITCH JACQUES
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07D213/42;A61K31/435;A61P31/18The present invention relates to polymorphic Forms B and P of atazanavir sulfate and methods for their preparation. The present invention is also directed towards pharmaceutical compositions comprising the novel polymorphs of atazanavir sulfate and methods of treating HIV infection by administering to a patient in need thereof a therapeutically effective amount of the polymorphic Forms B and P of atazanavir sulfate. The present invention also describes process for preparation of amorphous atazanavir sulfate.20100902WO(世界知识产权局)20110310US2005256202A1;US6087383A;US5849911A;WO2010079497A2C07D213/42WO2010IB53964GANGULY SOMENATH;SANTHAKUMAR RITA;CHANDRASHEKHAR T GWO2011027324A1RANBAXY LAB LTD;GANGULY SOMENATH;SANTHAKUMAR RITA;CHANDRASHEKHAR T G
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07F9/655;A61K31/655;A61P31/18The present invention relates to a crystalline form of fosamprenavir calcium. The crystalline form of the present invention is designated as Form II of fosamprenavir calcium. The present invention also relates to a process for the preparation of crystalline Form II of fosamprenavir calcium. The present invention further relates to a pharmaceutical composition comprising crystalline Form II of fosamprenavir calcium. The present invention relates further to a method of treating a HIV infection using crystalline Form II of fosamprenariv calium.20100629WO(世界知识产权局)20110106WO0004033A1;US6514953B1C07F9/655WO2010IB52974BHOGE SATISH MANOHAR;KSHIRSAGAR PRAKASH;RICHHARIYA SANTOSH;SINGH KAPTANWO2011001383A1RANBAXY LAB LTD;BHOGE SATISH MANOHAR;KSHIRSAGAR PRAKASH;RICHHARIYA SANTOSH;SINGH KAPTAN
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07F9/655;A61K31/665;A61P31/18The present invention relates to amorphous Fosamprenavir calcium and processes for its preparation, a pharmaceutical composition comprising it and a method for treating a HIV infection therewith.20100520WO(世界知识产权局)20101125WO0004033A1C07F9/655WO2010IB52251BHOGE SATISH MANOHAR;KSHIRSAGAR PRAKASH;RICHHARIYA SANTOSH;AGRAWAL ANSHUL;SINGH KAPTANWO2010134045A1RANBAXY LAB LTD;BHOGE SATISH MANOHAR;KSHIRSAGAR PRAKASH;RICHHARIYA SANTOSH;AGRAWAL ANSHUL;SINGH KAPTAN
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/4965Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics of drugs that undergo in vivo degradation by cytochrome P450 enzymes. Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Specifically, methods of inhibiting metabolic degradation of atazanavir sulphate for administering to a patient suffering from HIV infection are disclosed.20090916WO(世界知识产权局)20100325US2008113945A1;US2006084628A1A61K31/4965WO2009US57183LUDTKE DOUGLAS;DAGGER RAYMONDWO2010033614A1SEQUOIA PHARMACEUTICALS;LUDTKE DOUGLAS;DAGGER RAYMOND
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/47;A61K31/472;A61K31/496;A61K31/506;A61K31/52;A61K31/536;A61K31/7072The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ("Compound A") or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT/3TC, and a combination of PMPA/3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans.20050520WO(世界知识产权局)20051201EP1564210A1;WO0198275A2;WO0040563A1;US5985894AA61K31/47WO2005JP09719MATSUZAKI YUJI;WATANABE WATARU;IKEDA SATORU;KANO MITSUKIWO2005112930A1JAPAN TOBACCO INC;MATSUZAKI YUJI;WATANABE WATARU;IKEDA SATORU;KANO MITSUKI
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/505;A61K31/513;A61K31/52;A61K31/65;A61K31/675;A61K31/70;A61K45/06The present invention relates to the use of a dioxolane thymine compound according to the chemical structure of Formula (I): where R<1> is H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or phosphodiester group, for use in the treatment of HIV infections which exhibit resistance to 3TC and/or AZT. Preferably, compounds according to the present invention are combined with at least one anti-HIV agent which inhibits HIV by a mechanism other than through the inhibition of thymidine kinase (TK). These agents include those selected from among nucleoside reverse transcriptase inhibitors (NRTI), non-nucloeoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, among others. These agents are generally selected from the group consisting of 3TC (Lamivudine), AZT (Zidovudine), (-)-FTC, ddI (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-D4FC, NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV (Nelfinavir), APV (Amprenavir), LPV (Lopinavir), fuseon and mixtures thereof. The TK dependent agents, such as AZT and D4T, may be used in combination with one of the dioloxane thymine compounds according to the present invention, but the use of such agents may be less preferred. In preferred compositions according to the present invention, R<l> is preferably H or a C2-C18 acyl group or a monophosphate group. Pharmaceutical compositions and methods of reducing the likelihood that a patient at risk for contract an HIV infection will contract the infection are other aspects of the present invention.20031208WO(世界知识产权局)20040624A61K31/505WO2003US39029CHU CHUNG K;SCHINAZI RAYMOND FWO2004052296A2UNIV GEORGIA RES FOUND;UNIV EMORY;CHU CHUNG K;SCHINAZI RAYMOND F
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/00;A61K31/16;A61K31/4412;A61K38/14;A61K38/55;A61K45/06;A61P35/00;A61P39/04The invention discloses pharmaceutical compositions for the treatment of viral infections, in particular the human immunodeficiency virus (HIV). The compositions comprises a iron chelator and an antiviral agent. Suitable iron chelators are selected from the group of hydroxymates (such as deferoxamine), from hydroxypyridones (such as deferipone) or from nucleic acid binding chemotherapeutics (such as bleomycin). Suitable antiviral agents are protease inhibitors, preferably ritonavir, or reverse transcriptase inhibitors, preferably dideoxyinosine. The invention describes a pharmaceutical product for the treatment of viral infections, in particular of the human immunodeficiency virus (HIV). According to the invention, the pharmaceutical product comprises a compound that as active component contains an iron chelator. Suitable iron chelators are selected from the group of hydroxamates (such as deferoxamine), the family of the hydroxypyridinons (such as deferiprone), and the nucleic acid-binding chemotherapeutical products (such as bleomycine). A synergistic effect is obtained in vitro when in addition to the component containing the iron chelator, a product is used that contains another virus-inhibiting compound. As the antiviral agent a protease-inhibitor, preferably ritonavir, is considered. Another suitable antiviral agent is a reverse transcriptase inhibitor, preferably a dideoxyinosine.20000809WO(世界知识产权局)20010222A61K31/00WO2000NL00559VAN ASBECK BERNT SWEDER;MARX JOHANNES JOSEPHUS MARIAWO0112168A2FACULTEIT GENEESKUNDE UNIVERSI;ASBECK BERNT SWEDER VAN;MARX JOHANNES JOSEPHUS MARIA
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/426;A61K31/41The invention relates to ritonavir bis-hydrochloride, processes for the preparation of the ritonavir bis-hydrochloride, pharmaceutical compositions containing the ritonavir bis-hydrochloride and made from it, and methods of using the ritonavir bis-hydrochloride to inhibit HIV protease or enhance the pharmacokinetics of compounds which are metabolized by cytochrome P450 3A4.20111216US(美国)20131203US5674882A;US6232333B1;US6407252B1A61K31/426US201113328043ACQUASALIENTE MAURIZIO;HOULLEMARE DIDIER;ZHANG GEOFF;SINGAM PULLA;MORRIS JOHN;MARSH KENNAN;BABCOCK MARTIN;PAVLINA JOHN;SHI YI;GONG YUCHUANUS8598216B1ACQUASALIENTE MAURIZIO;HOULLEMARE DIDIER;ZHANG GEOFF;SINGAM PULLA;MORRIS JOHN;MARSH KENNAN;BABCOCK MARTIN;PAVLINA JOHN;SHI YI;GONG YUCHUAN;ABBVIE INC
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07C69/017;C07D209/48;C07D217/26;C07D263/14;C07D317/24;C07D327/10;C07D413/04;C07D413/06HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.19990428US(美国)20011016US5063208A;US5142056A;US5157041A;US5196438A;US5204471A;US5235039A;US5256783A;US5434265A;US5463104A;US5475136A;US5484926A;US5491166A;US5502061A;US5508407A;US5514802A;US5527829A;US5554653A;US5705647A;US5846993A;US5905077A;US5925759A;US5962725A;US6084107A;AU717637A;CA2075666A1;EP0337714A2;EP0346847A2;EP0356223A2;EP0361341A2;EP0402646A1;EP0432695A2;EP0432694A2;EP0434365A2;EP0490667A2;EP0498680A1;EP0526009A1;EP0533000A1;EP0539192A1;EP0560268A1;EP0579223A1;WO9108221A1;WO9304043A1;WO9313066A1;WO9323379A1;WO9404492A1;WO9405639A1;WO9509843A1;WO9628423A1;WO9711937A1;WO9711938A1;WO9730993A1C07C69/017US19990300835DEASON MICHAEL E;WHITTEN KATHLEEN RUS6303786B1AGOURON PHARMA;JAPAN TOBACCO INC
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/675;A61K31/427;A61K31/4418;A61K31/513;A61K31/536;A61K31/635The present invention relates to a pharmaceutical composition for treating the human immunodeficiency virus (HIV) in humans, including three or four active principles selected as: a nucleoside reverse transcriptase inhibitor (NRTI) selected from lamivudine and emtricitabine a nucleoside or nucleotide reverse transcriptase inhibitor (NRTI) selected from didanosine, abacavir and tenofovir and the combination of a boosted or unboosted protease inhibitor (PI) selected from lopinavir, fosamprenavir, atazanavir and darunavir or an non-nucleoside reverse transcriptase inhibitor (NNRTI) selected from efavirenz and etravirine or an integrase inhibitor for daily administration to said human being one to four days per week.20150623US(美国)20151231US2012270828A1;US2012283177A1A61K31/675US201514747621LEIBOWITCH JACQUESUS2015374727A1UNIVERSIT?? VERSAILLES SAINT QUENTIN EN YVELINES
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07D493/04;A61K9/20The present invention provides new pseudopolymorphic forms of darunavir as well as a novel amorphous form of darunavir, pharmaceutical compositions comprising these compounds, methods for their preparation and use thereof in treating retroviral infections, in particular, HIV infection.20141124US(美国)20150528US8921415B2C07D493/04US201414551497MAROM EHUDUS2015148412A1MAPI PHARMA LTD
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/7072;A61K31/39;A61K31/47;A61K31/472;A61K31/496;A61K31/506;A61K31/52;A61K31/536;A61K31/675The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (??Compound A??) or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT/3TC, and a combination of PMPA/3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans.20131212US(美国)20141211A61K31/7072US201314104398MATSUZAKI YUJI;WATANABE WATARU;IKEDA SATORU;KANO MITSUKIUS2014364389A1JAPAN TOBACCO INC
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/4418;A61K45/06;B29B9/12Disclosed are compressed tablets containing atazanavir sulfate and an acidifying agent, optionally with another active agent, e.g., anti-HIV agents, and optionally with precipitation retardant agents. Also disclosed are processes for making the tablets, and methods of treating HIV.20110407US(美国)20130808A61K31/4418US201113639544NIKFAR FARANAK;HUSSAIN MUNIR ALWAN;QIAN FENGUS2013203759A1NIKFAR FARANAK;HUSSAIN MUNIR ALWAN;QIAN FENG
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/34;A61K31/427;A61P31/14;A61P31/18;C07D493/04The present invention provides new pseudopolymorphic forms of darunavir as well as a novel amorphous form of darunavir, pharmaceutical compositions comprising these compounds, methods for their preparation and use thereof in treating retroviral infections, in particular, HIV infection.20120725US(美国)20130124A61K31/34US201213557991MAROM EHUDUS2013023570A1MAPI PHARMA LTD;MAROM EHUD
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/635;A61P31/14;A61P31/18;C07D493/04The present invention provides new pseudopolymorphic forms of darunavir as well as a novel amorphous form of darunavir, pharmaceutical compositions comprising these compounds, methods for their preparation and use thereof in treating retroviral infections, in particular, HIV infection.20091208US(美国)20120209A61K31/635US200913146727MAROM EHUDUS2012035142A1MAROM EHUD;MAPI PHARMA LTD
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/635;A61K31/4418;A61K31/4433;A61K31/4725;A61P31/18;C07D213/42;C07D401/12;C07D405/12;C07D493/04Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature. Exemplary potent HIV protease inhibitors are mono-m-PEG3-atazanavir, mPEGn-N-darunavir (wherein n is 3 or 5), mPEGn-NHCO-saquinavir (wherein n is 5 or 7), and di-mPEG3-atazanavir.20090917US(美国)20110811US8598364B2;US2005136031A1;US5672662A;US2004224900A1A61K31/635US200913119079JUDE-FISHBURN C SIMONE;VANDER VEEN LAURIE A;RILEY TIMOTHY AUS2011195940A1NEKTAR THERAPEUTICS
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/4418;A61K31/16;A61P31/12;C07C231/02;C07C243/26;C07D213/42A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.20101008US(美国)20110526US7838678B2;US4800084A;US5489436A;US2004022855A1;US4022776A;US5428048A;US4847265A;US5541205A;US6086919A;US6087383A;US2002094992A1;US658435A;US3980637A;US2005214373A1;US5158777A;US6136345A;US6316438B1;US2005256314A1;US5849911A;US2005266080A1;US2005288343A1A61K31/4418US20100900588KIM SOOJIN;LOTZ BRUCE T;MALLEY MARY F;GOUGOUTAS JACK Z;DAVIDOVICH MARTHA;SRIVASTAVA SUSHIL KUS2011124689A1SQUIBB BRISTOL MYERS CO
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/551;A61K31/522The invention relates to an anti-HIV combination comprising (i) tenofovir or its disoproxil fumarate derivative (ii) ritonavir and (iii) TMC 114, useful for the treatment or prevention of HIV infections. It further relates to pharmaceutical formulations containing such combinations.20050708US(美国)20070906A61K31/551US20050571599HOETELMANS RICHARD MARINUS WUS2007208009A1HOETELMANS RICHARD MARINUS W
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/47;C12N9/99;A61K39/00;A61P31/18;A61P43/00;C07D217/26;C07D239/10;C07D277/28;C07D307/20;C07D401/12;C07D401/14;C07D403/12;C07D405/12;C07D417/14;C07D495/04;C07K14/00;C07K14/765;C07K14/795;C07K16/00;C07K16/38;C07K16/44;C12N5/10;C12P21/08Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.20070126US(美国)20070628US2003010088A1A61K31/47US20070627572SIGLER GERALD F;HUI RAYMOND A;DERAS INA;ROOT RICHARD T;GHOSHAL MITALI;HUBER ERASMUS;VON DER ELTZ HERBERT W;METZ SIGRUN;KERN PETERUS2007149565A1SIGLER GERALD F;HUI RAYMOND A;DERAS INA;ROOT RICHARD T;GHOSHAL MITALI;HUBER ERASMUS;VON DER ELTZ HERBERT W;METZ SIGRUN;KERN PETER
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07D403/02;C07K16/38;C07K16/44Activated haptens useful for generating immunogens to the HIV protease inhibitor atazanavir, immunogens useful for producing antibodies to atazanavir, and antibodies and labeled conjugates useful in immunoassays for determination of atazanavir. The haptens feature an activated functionality at the central, non-terminal hydroxyl group.20061222US(美国)20070621US6087383A;US6635745B2C07D403/02US20060615092ROOT RICHARD T;HUI RAYMOND AUS2007142641A1ROCHE DIAGNOSTICS OPERATIONS
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/47;A61K31/472;A61K31/496;A61K31/506;A61K31/52;A61K31/536;A61K31/7072The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ("Compound A") or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT/3TC, and a combination of PMPA/3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans.20050520US(美国)20051229US7176220B2;US2005054645A1;US6248736B1;US6248739B1;US2004127708A1;US2002103220A1;US3472859A;US2005239819A1;US5985894AA61K31/47US20050133463MATSUZAKI YUJI;WATANABE WATARU;IKEDA SATORU;KANO MITSUKIUS2005288326A1MATSUZAKI YUJI;WATANABE WATARU;IKEDA SATORU;KANO MITSUKI
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/16;C07C231/02;C07C243/26;C07D213/42A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.20050502US(美国)20051117US4800084A;US5489436A;US6727271B2;US6395767B2;US5428048A;US6753012B2;US4847265A;US5541205A;US6086919A;US6087383A;US2002094992A1;US6414002B1;US6429210B1;US2005214373A1;US5158777A;US6136345A;US6316438B1;US6653314B2;US2005256314A1;US5849911A;US6670344B2;US2005266080A1;US2005288343A1A61K31/16US20050119558KIM SOOJIN;LOTZ BRUCE T;MALLEY MARY F;GOUGOUTAS JACK Z;DAVIDOVICH MARTHA;SRIVASTAVA SUSHIL KUS2005256202A1KIM SOOJIN;LOTZ BRUCE T;MALLEY MARY F;GOUGOUTAS JACK Z;DAVIDOVICH MARTHA;SRIVASTAVA SUSHIL K
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/505;A61K31/513;A61K31/52;A61K31/65;A61K31/675;A61K31/70;A61K45/06The present invention relates to the use of a dioxolane thymine compound according to the chemical structure of Formula (I): where R<SUP>1 </SUP>is H, an acyl group, a C<SUB>1</SUB>-C<SUB>20 </SUB>alkyl or ether group, a phosphate, diphosphate, triphosphate or phosphodiester group, for use in the treatment of HIV infections which exhibit resistance to 3TC and/or AZT. Preferably, compounds according to the present invention are combined with at least one anti-HIV agent which inhibits HIV by a mechanism other than through the inhibition of thymidine kinase (TK). These agents include those selected from among nucleoside reverse transcriptase inhibitors (NRTI), non-nucloeoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, among others. These agents are generally selected from the group consisting of 3TC (Lamivudine), AZT (Zidovudine), (-)-FTC, ddI (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-D4FC, NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV (Nelfinavir), APV (Amprenavir), LPV (Lopinavir), fuseon and mixtures thereof. The TK dependent agents, such as AZT and D4T, may be used in combination with one of the dioloxane thymine compounds according to the present invention, but the use of such agents may be less preferred. In preferred compositions according to the present invention, R<SUP>1 </SUP>is preferably H or a C<SUB>2</SUB>-C<SUB>18 </SUB>acyl group or a monophosphate group. Pharmaceutical compositions and methods of reducing the likelihood that a patient at risk for contract an HIV infection will contract the infection are other aspects of the present invention.20050401US(美国)20050922US5276151A;US6350753B1;US6855821B2;US5041449A;US7119202B1;US5852027AA61K31/505US20050530088CHU CHUNG K;SCHINAZI RAYMOND FUS2005209196A1CHU CHUNG K;SCHINAZI RAYMOND F
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/522;A61K31/551The present invention includes a group of novel compounds that are demonstrated to potently and selectively inhibit HIV integrase (IN) activity in vitro and to potently inhibit HIV replication in live, cultured cells at non-toxic concentrations. The novel compounds disclosed include 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-L-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-L-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-L-tartaric acid, 2,3-di-(3,4,5-trihydroxybenzoyl-L-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-L-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidine succinic acid, 2,3-dicaffeoyl-L-serine, bis-dicaffeoyl-L-isoserine and 1,4-dicaffeoyl-L-lysine. Tests of integrase inhibitors with 2',3'-dideoxycytidine, zidovudine and nelfinavir (protease inhibitor) indicated a potent synergy against reverse transcriptase inhibitor resistant virus. The potential benefit from the addition of integrase inhibitors to combination drug therapies is significant.20030925US(美国)20050303US5705647A;US4724232A;US5759842A;US5663161AA61K31/522US20030672724ROBINSON W EDWARD;KING PETER J;REINECKE MANFRED GUS2005049242A1
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/426;A61K9/14;A61K9/16;A61K9/20;A61K31/4425;A61K31/4433;A61K31/472;A61K31/4725;A61K31/496;A61K31/505;A61K47/00;A61K47/02;A61P31/18FIELD: pharmaceutics.SUBSTANCE: invention relates to the chemical and pharmaceutical industry, and more particularly to a pharmaceutical composition for preventing and treating HIV infection. Pharmaceutical composition contains a HIV protease inhibitor representing ritonavir and magnesium aluminometasilicate in a weight ratio of 1:(0.5?C1.5). Magnesium aluminometasilicate is Neusilin. Ritonavir includes polymorphic form 1, polymorphic form 2, or combinations thereof. Pharmaceutical composition is prepared in solid form.EFFECT: composition, according to the invention, using magnesium aluminometasilicate Neusilinprovides close solubility characteristics, regardless of the polymorphic form of ritonavir used.9 cl, 1 tbl, 2 ex20170320RU(俄罗斯联邦)20180806A61K31/426RU20170109102ZOLOTOV SERGEJ ANATOLEVICH;LUBENETS NADEZHDA LEONIDOVNA;IGNATEV ALEKSEJ VLADIMIROVICHRU2663466C1OBSHCHESTVO S OGRANICHENNOJ OTVETSTVENNOSTYU MBA GRUPP
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/427;A61K9/08;A61K9/52;A61K31/34;A61K38/06;A61P31/12;A61P31/18;B82B1/00FIELD: medicine.SUBSTANCE: group of inventions refers to the long-term use of an parenteral formulation for producing a medicinal preparation for treating a HIV-infected individual with the above preparation applicable for subcutaneous or intramuscular injections and consists of brecanavir, or its salt in the form of an aqueous micro- or nanoparticle suspension containing Polysorbate 20, and is administered at regular intervals from 6 to 12 months, and to the above pharmaceutical composition.EFFECT: reducing the number of injections of the composition (preparation) in the absence of the additional agent ritonavir.7 cl, 4 dwg, 4 tbl20100922RU(俄罗斯联邦)20151120A61K31/427RU20120116070BART LIVEN EHLVIRE KOLETT;KRAUS GJUNTERRU2569058C2TIBOTEK FARMAS JUTIKALZ
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07D493/04;A61K31/34;A61K31/365;A61K31/4164;A61K31/427;A61K31/496;A61K31/635;A61K45/00;A61P31/12;A61P31/18;A61P43/00Disclosed is a combination comprising a hexahydrofuro2,3-bfuranyl containing HIV protease inhibitor of formula (4) and ritonavir. The combination is used in the manufacture of medicaments for the treatment of diseases associated with retrovirus infection in a mammal.20021212NZ(新西兰)20060428C07D493/04NZ20020533826VAN DER GEEST RONALD;STOFFELS PAUL;GROEN CORNELIS;JOCHMANS DIRK EDWARD DESIRENZ533826ATIBOTEC PHARM LTD
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07D213/127;A61K31/16;A61K31/44;C07C231/02;C07C243/26;C07D213/42A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol. ? KIPO & WIPO 200720050503KR(韩国)20070111C07D213/127KR20067025370KIM SOO JIN;LOTZ BRUCE T;MALLEY MARY F;GOUGOUTAS JACK Z;DAVIDOVICH MARTHA;SRIVASTAVA SUSHIL KKR20070006935ASQUIBB BRISTOL MYERS CO
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/425;A61K9/48;A61K31/17;A61K31/341;A61K31/426;A61K31/4433;A61K31/45;A61K31/4545;A61K31/47;A61K31/4704;A61K31/4709;A61K31/472;A61K31/4725;A61K31/496;A61K31/513;A61K31/535;A61K31/5375;A61K31/55;A61K31/551;A61K31/635;A61K38/05;A61K38/55;A61K45/08;A61K47/10;A61K47/12;A61K47/26;A61K47/42;A61K47/44;A61P31/18;A61P43/00A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).19990520KR(韩国)20050323A61K31/425KR19997004469KR100478075B1
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07D249/14;A61K31/4196;A61K31/428;A61K31/4355;A61K31/4365;A61K31/4375;A61K31/4439;A61K31/454;A61K31/4545;A61K31/4709;A61K31/4725;A61K31/473;A61K31/496;A61K31/497;A61K31/498;A61K31/501;A61K31/502;A61K31/5025;A61K31/506;A61K31/517;A61K31/519;A61K31/5377;A61K31/63;A61P9/00;A61P13/12;A61P15/00;A61P17/06;A61P19/02;A61P19/10;A61P27/02;A61P27/12;A61P29/00;A61P35/00;A61P35/02;A61P43/00;C07D401/04;C07D403/04;C07D413/12;C07D417/04;C07D471/04;C07D491/048;C07D491/052;C07D495/04;C07D495/14PROBLEM TO BE SOLVED: To provide oral solid dosage forms for human immunodeficiency virus (HIV) protease inhibitors which have suitable oral bioavailability and stability and which do not necessitate high vehicle volumes.SOLUTION: An oral solid pharmaceutical dosage form includes a solid dispersion product of: an HIV protease inhibitor such as ritonavir and lopinavir a water-soluble polymer, such as a copolymer of N-vinyl pyrrolidone and vinyl acetate, having a Tg of at least about 50°C and a surfactant, such as sorbitan fatty acid ester.SELECTED DRAWING: None20151207JP(日本)20160526JP2006515313A;WO2006034116A1;WO2006050249A1C07D249/14JP20150238896DANE GOFF;ZHANG JING;SYLVAIN CATHERINE;SINGH RAJINDER;SACHA HOLLAND;YU JIAXIN;THILO HECKRODT;DING PINGYUJP2016094437ARIGEL PHARMACEUTICALS INC
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/427;A61K9/24;A61K9/48;A61K31/34;A61P31/18;A61P43/00PROBLEM TO BE SOLVED: To provide a novel antiretroviral combination pharmaceutical composition.SOLUTION: A combination therapy pharmaceutical composition contains a solid dosage form containing ritonavir or a pharmaceutically acceptable salt thereof and ester, and darunavir or a pharmaceutically acceptable salt thereof and ester, wherein the dosage form is a tablet form, which comprises a first layer containing the ritonavir, and a second layer containing the darunavir. It is effective for treatment-naive and treatment experienced patients. It is non-toxic and is highly potent against wide variety of and multidrug-resistant HIV (human immunodeficiency virus) strains and further is readily to produce.20140806JP(日本)20150115JP2005511723A;WO2007068934A2;JP2007504142AA61K31/427JP20140160671AMAR LULLA;GEENA MALHOTRAJP2015007071ACIPLA LTD
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07D277/28;A61K31/426;A61K31/427;A61P31/18;A61P37/04;C07D277/24;C07D277/30;C07D277/36;C07D277/40;C07D277/42;C07D417/12PROBLEM TO BE SOLVED: To provide a new crystalline polymorph of ritonavir, which is an inhibitor of human immunodeficiency virus (HIV) protease and HIV infection, and methods for its preparation.SOLUTION: The methods for preparing a new crystalline polymorph of ritonavir comprise crystallization by adding a poor solvent to ritonavir dissolved in a good solvent. The new crystalline polymorph of ritonavir has characteristic peaks in powder X-ray diffraction patterns at values of 2?? of 8.67???0.1??, 9.88???0.1??, 16.11???0.1??, 16.70???0.1??, 17.36???0.1??, 17.78???0.1??, 18.40???0.1??, 18.93???0.1??, 20.07???0.1??, 20.65???0.1??, 21.71???0.1?? and 25.38???0.1??. For the preparation, hexane is added to a solution of ritonavir Form I in methylene chloride or methanol.20131211JP(日本)20140424WO9639398A1;JPH08505844AC07D277/28JP20130255680BAUER JOHN F;SALEKI-GERHARDT AZITA;NARAYANAN BIKSHANDARKOIL A;CHEMBURKAR SANJAY R;PATEL KETAN;SPIWEK HARRY O;BAUER PHILIP E;ALLEN KIMBERLY AJP2014074047AABBVIE INC
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/4439;A61K31/4709;A61K31/662;A61K31/7068;A61K31/7072;A61K31/708;A61P31/18Anti-HIV composition contains 2-carbamoyloxymethyl-5-(3,5-dichlorophenylthio)-4-isopropyl-1-(pyridin-4-yl)methyl-1H-imidazole (CDIMI) or its salt and at least one other anti-HIV agent. Preferably the additional anti-HIV agent is preferably AZT, ddI, ddC, 3TC, saquinavir and/or foscarnet.19970314HU(匈牙利)20000428A61K31/4439HU19990002175FUJIWARA TAMIOHU9902175A2
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/5025;A61K45/06;A61P31/18The present invention relates to pharmaceutical antiretroviral compositions comprising a combination of antiretroviral agents (darunavir, dolutegravir and ritonavir), the manufacturing process thereof and use of the said compositions for the prevention, treatment or prophylaxis of HIV infection.20170727EP(欧洲专利局)20190619A61K31/5025EP20170838879BANDI PARTHASARATHI REDDY;PODILE KHADGAPATHI;TIWARI SUNIL DEVIPRASAD;SHETIYA PRAKASH;MEDUM BALAKRISHNAIAHEP3496718A1HETERO LABS LTD
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07C303/40;C07C311/41The present invention relates to an industrially feasible and economically viable process for the preparation of (1S,2R)-3-[4-aminophenyl)-sulfonylamino]-2-hydroxy-1-(phenyl-methyl)propyl] amine of formula I and its salt thereof and optionally converting it to HIV-protease inhibitors like Darunavir, Amprenavir or its prodrug Fosamprenavir.20150827EP(欧洲专利局)20160323WO2011048604A2;WO2005063770A1;WO2013108105A2;US5843946A;US6248775B1;US7772411B2;WO2013011485A1C07C303/40EP20150182635AGARWAL NAND LAL;HIRPARA HITIN MAGANBHAI;MISTRI PRANAV POPATLAL;PATEL NITIN MAGANBHAIEP2998291A1ZCL CHEMICALS LTD
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07F9/655;A61K31/655;A61P31/18The present invention relates to a crystalline form of fosamprenavir calcium. The crystalline form of the present invention is designated as Form II of fosamprenavir calcium. The present invention also relates to a process for the preparation of crystalline Form II of fosamprenavir calcium. The present invention further relates to a pharmaceutical composition comprising crystalline Form II of fosamprenavir calcium. The present invention relates further to a method of treating a HIV infection using crystalline Form II of fosamprenariv calium.20100629EP(欧洲专利局)20120509C07F9/655EP20100740308BHOGE SATISH MANOHAR;KSHIRSAGAR PRAKASH;RICHHARIYA SANTOSH;SINGH KAPTANEP2448949A1RANBAXY LAB LTD
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07F9/655;A61K31/665;A61P31/18The present invention relates to amorphous Fosamprenavir calcium and processes for its preparation, a pharmaceutical composition comprising it and a method for treating a HIV infection therewith.20100520EP(欧洲专利局)20120328C07F9/655EP20100724900BHOGE SATISH MANOHAR;KSHIRSAGAR PRAKASH;RICHHARIYA SANTOSH;AGRAWAL ANSHUL;SINGH KAPTANEP2432788A1RANBAXY LAB LTD
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/4965;A61K9/14Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics of drugs that undergo in vivo degradation by cytochrome P450 enzymes. Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Specifically, methods of inhibiting metabolic degradation of atazanavir sulphate for administering to a patient suffering from HIV infection are disclosed.20090916EP(欧洲专利局)20110629US2008113945A1;US2007218138A1A61K31/4965EP20090815132LUDTKE DOUGLAS;DAGGER RAYMONDEP2337565A1SEQUOIA PHARMACEUTICALS
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/337;C07D243/04;A61K31/335;A61K31/336;A61K31/34;A61K31/341;A61K31/395;A61K31/425;A61K31/426;A61K31/44;A61K31/4427;A61K31/445;A61K31/453;A61K31/47;A61K31/472;A61K31/498;A61K31/535;A61K31/5375;A61K31/55;A61K31/7048;A61K38/05;A61K38/06;A61K38/55;A61K45/06;A61P31/12;A61P31/18;C07D217/22;C07D277/24;C07D277/28;C07D295/08;C07D295/18;C07D303/46;C07D307/20;C07D401/14;C07D417/12;C08F2/34There is described a combination of ritonavir or a pharmaceutically acceptable salt thereof in combination with another HIV protease inhibitor, formulated as a single or separate composition, for use in the inhibition or treatment of an HIV infection or AIDS in a human host.19960628EP(欧洲专利局)20140108A61K31/337EP20100185624NORBECK DANIEL W;KEMPF DALES J;LEONARD JOHN M;BERTZ RICHARD JEP2295052B1ABBVIE INC
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/47;A61K31/472;A61K31/496;A61K31/506;A61K31/52;A61K31/536;A61K31/7072;A61P31/18;A61P43/00The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ("Compound A") or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT/3TC, and a combination of PMPA/3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans.20050520EP(欧洲专利局)20100922EP1564210A1;WO0198275A2;WO0040563A1;US5985894A;WO02070486A1;WO0236734A2;WO02055079A2;US3472859A;JPS482672A;JP2002534416A;WO0040561A1;US6248739B1;EP1140850A1;JP2002534417A;US6248736B1;EP1140851A1;US2002103220A1;JPH04360872A;EP0498721B1A61K31/47EP20100161346MATSUZAKI YUJI;WATANABE WATARU;IKEDA SATORU;KANO MITSUKIEP2229945A1JAPAN TOBACCO INC
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07D493/04The present invention relates to process for the preparation of Darunavir or a solvate thereof of Formula (I) using a novel intermediate (3R,3aS,6aR)-hexahydrofuro2,3-bfuran-3-yl (2S,3R)-4-(4-(1,3-dioxoisoindolin-2-yl)-N-isobutylphenylsulfonamido)-3 -hydroxy- 1 -phenylbutan-2- ylcarbamate Compound of formula (II): The present invention also relates to the process for the preparation of novel intermediates (3R,3aS,6aR)-hexahydrofuro2,3-bfuran-3-yl (2S,3R)-4-(4-(l,3-dioxo iso indolin-2-yl)-N-isobutylphenylsulfonamido)-3 -hydroxy-1-phenylbutan-2-ylcarbamate Compound of formula (II). Darunavir or its solvate of formula (I) are useful therapeutic agent and used in treatment of antiviral diseases.20170721WO(世界知识产权局)20180125C07D493/04WO2017IB54420CHIGURUPATI KRISHNA PRASAD;AREVELI SRINIVAS;GILLA GOVERDHAN;RAPOLU RAJESH KUMAR;VETUKURI PRASADA RAJU VNKVWO2018015929A1GRANULES INDIA LTD
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/513;A61K9/16;A61K9/20;A61K9/28;A61K31/426;A61K31/427The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.20060221EP(欧洲专利局)20110216A61K31/513EP20100184860ROSENBERG JOERG;REINHOLD ULRICH;LIEPOLD BERND;BERNDL GUNTHER;ALANI LAMAN;GHOSH SOUMOJEET;BREITENBACH JOERGEP2283844A1ABBOTT LAB
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/425;A61K9/48;A61K31/17;A61K31/426;A61K31/427;A61K31/4427;A61K31/4433;A61K31/4709;A61K31/472;A61K31/4725;A61K31/496;A61K31/513;A61K31/5375;A61K31/551;A61K31/63;A61K45/00;A61K47/10;A61K47/12;A61K47/30;A61K47/42;A61P31/00;A61P31/18;A61P43/00Improved pharmaceutical compositions are provided comprising one or more HIV protease inhibiting compounds having improved dissolution properties in a mixture of a fatty acid, ethanol, and water.20000525EP(欧洲专利局)20060705A61K31/425EP20000937743ALANI LAMAN A;GHOSH SOUMOJEETEP1183026B1ABBOTT LAB
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/425;A61K9/48;A61K31/17;A61K31/426;A61K31/427;A61K31/4433;A61K31/4709;A61K31/472;A61K31/4725;A61K31/496;A61K31/513;A61K31/5375;A61K31/551;A61K31/63;A61K45/00;A61K47/10;A61K47/12;A61K47/30;A61K47/42;A61P31/18;A61P43/00In the present invention, there is provided a pharmaceutical composition having improved dissolution comprising ritonavir or a combination of ritonavir and another HIV protease inhibiting compound, a pharmaceutically acceptable organic solvent comprising 40 to 75 percent by weight (based on the solution total weight) of a long chain fatty acid and from about 1 to about 15 percent by weight (based on the solution total weight) of ethanol, water in the amount of from about 0.4 to about 3.5 percent by weight of the total solution and optionally a pharmaceutically acceptable surfactant.20000525CZ(捷克共和国)20100106CZ294246B6;CZ298188B6;WO9525504A1;WO9822106A1;WO9509614A1;WO9701349A1;WO9607696A1A61K31/425CZ20010004293ALANI LAMAN A;GHOSH SOUMOJEETCZ301308B6ABBOTT LAB
治疗用药 -> 化学药 -> 抑制HIV蛋白酶C07D277/28;A61K9/48;A61K31/00;A61K31/425;A61K31/426;A61K31/427;A61K31/47;A61K31/472;A61K31/4725;A61K31/496;A61K31/551;A61K31/635;A61P31/12;A61P37/04;A61P43/00A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a pharmaceutically acceptable alcohol. The composition can optionally comprise a pharmaceutically acceptable acid or a combination of pharmaceutically acceptable acids. The solution can optionally be encapsulated in hard gelatin capsules or soft elastic gelatin capsules. The solution can optionally be granulated with a pharmaceutically acceptable granulating agent.19940830EP(欧洲专利局)19960703C07D277/28EP19940927973AL-RAZZAK LAMAN A;MARSH KENNAN C;MANNING LOURDES P;KAUL DILIPEP0719142A1ABBOTT LAB
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/425;A61K9/48;A61K31/17;A61K31/426;A61K31/427;A61K31/4433;A61K31/4709;A61K31/472;A61K31/4725;A61K31/496;A61K31/513;A61K31/5375;A61K31/551;A61K31/63;A61K45/00;A61K47/10;A61K47/12;A61K47/30;A61K47/42;A61P31/18;A61P43/00Improved pharmaceutical compositions are provided comprising one or more HIV protease inhibiting compounds having improved dissolution properties in a mixture of a fatty acid, ethanol, and water.20000525EP(欧洲专利局)20090422A61K31/425EP20060114684ALANI LAMAN A;GHOSH SOUMOJEETEP1733725B1ABBOTT LAB
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/513;A61K9/16;A61K9/20;A61K9/28;A61K31/426;A61K31/427The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.20060221EP(欧洲专利局)20100714WO2005039551A2;WO2004032903A2;WO0134119A2;US2001051721A1A61K31/513EP20100159672ROSENBERG J?RG;REINHOLD ULRICH;LIEPOLD BERND;BERNDL GUNTHER;BREITENBACH J?RG;ALANI LAMAN;GHOSH SOUMOJEETEP2206500A1ABBOTT LAB
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/675The present invention relates to an oral unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir and a monolithic tablet comprising Darunavir and Ritonavir and their use to treat HIV infection.20140828WO(世界知识产权局)20150305US5922695A;US5935946A;US5977089A;US6043230A;US8592397B2;US8716264B2;US2014037732A1;US5210085A;US5814639A;US5914331A;US6642245B1;US7402588B2;US6335460B1;US6248775B1;US5843946A;USRE43596E;WO2013004816A1;US5541206A;US5648497A;US6037157A;US7364752B1;US8268349B2;WO2011061302A1;WO2011061303A1;WO9630025A1;WO2006135933A2;WO2009081174A2;WO2013057469A1;EP1097148A2A61K31/675WO2014IB01637SHAHAR NITZAN;HARONSKY ELINA;HRAKOVSKY JULIAWO2015028875A2TEVA PHARMA
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K47/22;A61K9/20;A61K31/427;A61K31/4418;A61K31/5377;A61K47/12Disclosed are compressed tablets containing atazanavir sulfate and an acidifying agent, optionally with another active agent, e.g., anti-HIV agents, and optionally with precipitation retardant agents. Also disclosed are processes for making the tablets, and methods of treating HIV.20141125US(美国)20150319WO2009084036A2A61K47/22US201414552772NIKFAR FARANAK;HUSSAIN MUNIR ALWAN;QIAN FENGUS2015080399A1SQUIBB BRISTOL MYERS CO
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K47/22;A61K9/20;A61K31/427;A61K31/4402;A61K31/4418;A61K31/5377;A61K45/06;A61K47/12;B29B9/12Disclosed are compressed tablets containing atazanavir sulfate and an acidifying agent, optionally with another active agent, e.g., anti-HIV agents, and optionally with precipitation retardant agents. Also disclosed are processes for making the tablets, and methods of treating HIV.20171002US(美国)20180125A61K47/22US201715722068NIKFAR FARANAK;HUSSAIN MUNIR ALWAN;QIAN FENGUS2018021436A1BRISTOL-MYERS SQUIBB COMPANY
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K47/22;A61K9/20;A61K31/427;A61K31/4402;A61K31/4418;A61K31/5377;A61K45/06;A61K47/12;B29B9/12Disclosed are compressed tablets containing atazanavir sulfate and an acidifying agent, optionally with another active agent, e.g., anti-HIV agents, and optionally with precipitation retardant agents. Also disclosed are processes for making the tablets, and methods of treating HIV.20181219US(美国)20190502A61K47/22US201816225493NIKFAR FARANAK;HUSSAIN MUNIR ALWAN;QIAN FENGUS2019125875A1SQUIBB BRISTOL MYERS CO
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K47/48;A61P31/18Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature. Exemplary potent HIV protease inhibitors are mono-m-PEG3-atazanavir, mPEGn-N-darunavir (wherein n is 3 or 5), mPEGn-NHCO-saquinavir (wherein n is 5 or 7), and di-mPEG3-atazanavir.20090917WO(世界知识产权局)20100603FR2773994A1;WO2008112289A2A61K47/48WO2009US05208JUDE-FISHBURN C SIMONE;VANDERVEEN LAURIE ANNE;RILEY TIMOTHY AWO2010033219A3NEKTAR THERAPEUTICS;JUDE-FISHBURN C SIMONE;VANDERVEEN LAURIE ANNE;RILEY TIMOTHY A
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K9/00;A61K9/20;A61K9/28;A61K31/551Provided is a solid unit oral pharmaceutical dosage form of saquinavir mesylate comprising from about 60% to about 80% micronized saquinavir mesylate based on the mesylate salt, from about 4% to about 8% of a pharmaceutically acceptable water soluble binder, a pharmaceutically acceptable disintegrant, and a pharmaceutically acceptable carrier, wherein each percentage is of the kernel weight of the pharmaceutical dosage form. Also provided is a similar dosage form, wherein the saquinavir mesylate is in an amount of frorn about 200 mg to about 700 mg calculated as saquinavir free base. Further provided is the process of making the dosage form and use of the dosage form for the treatment of HIV mediated disease.20040705NZ(新西兰)20080430A61K9/00NZ20040544585ALBANO ANTONIO A;INFELD MARTIN HOWARD;PHUAPRADIT WANTANEE;SHAH NAVNIT HARGOVINDAS;ZHANG LINNZ544585AHOFFMANN LA ROCHE
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/675;A61K9/20;A61K9/28;A61K31/427;A61K31/513;A61K31/635The present invention relates to an oral unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir and a monolithic tablet comprising Darunavir and Ritonavir and their use to treat HIV infection.20160223US(美国)20160714A61K31/675US201615051381SHAHAR NITZAN;HARONSKY ELINA;HRAKOVSKY JULIAUS2016199396A1TEVA PHARMA
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/4418;A61K9/20;A61K9/28;A61K31/427;A61K31/551;A61K38/05;C07D213/42Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV.20171121US(美国)20180315A61K31/4418US201715819070KOO OTILIA MAY YUE;NIKFAR FARANAK;DIAZ STEVENUS2018071270A1SQUIBB BRISTOL MYERS CO
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/4418;A61K9/20;A61K9/24;A61K31/427Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV.20140702US(美国)20151112A61K31/4418US201414322478KOO OTILIA MAY;NIKFAR FARANAK;DIAZ STEVENUS2015320731A1SQUIBB BRISTOL MYERS CO
治疗用药 -> 化学药 -> 抑制HIV蛋白酶A61K31/4418;A61K9/20;A61K9/28Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV.20150330US(美国)20150723US2005256202A1;US5681583A;US2005026910A1;US2007059360A1;US2857313AA61K31/4418US201514673171KOO OTILIA MAY YUE;NIKFAR FARANAK;DIAZ STEVENUS2015202191A1SQUIBB BRISTOL MYERS CO

数据更新频率

年度更新